20 8 月, 2022

复锐医疗科技公布2022中期业绩

HONG KONG, CHINA, Aug 20, 2022 - (亚太商讯 via SEAPRWire.com) - 2022年8月19日，复锐医疗科技有限公司（英文“Sisram Medical”；简称“公司”或“复锐医疗科技”，股份代号：1696.HK，连同其附属公司统称“集团”），今日公布截至2022年6月30日止六个月（“报告期”）之中期业绩。复锐医疗科技是一家全球化的美丽健康集团，其独特的美丽健康生态系统提供多元化产品组合，打造以客户为中心的品牌，业务包括能量源医美设备、注射填充、美容及数字牙科、个人护理等。公司将于北京时间8月22日（周一）下午16:30举办中期业绩发布电话会议（中文场），登记信息请参考内文。财务亮点：-- 截至2022年6月30日，期内收入实现174.5百万美元，较2021年同比增长39.3%。-- 截至2022年6月30日，期内归母净利润达到20.6百万美元，较2021年同比增长25.9%。-- 截至2022年6月30日，期内直销收入占总收入64.8%，2021年同期为59.7%。-- 在北美地区及亚太地区销售业绩均取得大幅增长。截至2022年6月30日，北美地区所得收入为69.9百万美元，较2021年同比增长42.2%；亚太地区所得收入为47.9百万美元，较2021年同比增长42.0%。业务亮点：-- 持续研发投入及创新，成功上市三款新产品：“Alma TED™”, “CBD+ Professional Skincare Solution™”和“LMNT one™”。- Alma TED™是一款基于超声波的能量平台，采用Impact Delivery™设计的专有探头，可提供非侵入性无创治疗，以解决当今社会日益增长的脱发问题。- “CBD+”是首个结合全光谱大麻二酚（CBD）系统优势的专业护肤解决方案，主要作为搭配耗材，于能量源设备治疗后使用，能显著改善皮肤发红并舒缓敏感肌肤表层。- LMNT One™采用了经典的美容科技组合，LED红光、NIR近红外光及 micro pulses微脉冲技术，经临床验证可以有效提升肌肤微循环，促进胶原蛋白新生，使消费者在家中即可享受舒适医美体验。-- 差异化丰富注射填充产线：期内于中国投资布局丝素蛋白透明质酸钠复合凝胶及面部埋线产品，该类产品为丝素蛋白再生材料于医美行业的创新性探索，未来可与现有医美产品形成组合拳。-- 进一步扩大美容及数字牙科业务线：期内投资扩展产品组合至创新生物材料，结合计算机辅助美学设计、修复产品以及无创贴面等高端技术，完善集团美容及数字牙科业务的产品组合并推动该业务板块的快速发展。-- 进一步扩大直销布局：在战略性市场持续扩展直销布局，不断贴近终端消费者，是公司长期坚持的发展战略。期内，集团新设英国直销办公室，成为美丽健康生态圈又一新拓展区域，以满足客户对集团产品和服务的强劲需求。-- 加强品牌建设，提升用户黏性及活跃度：通过Alma Academy活动，与全球各地数百名医生学者及商业合作伙伴探讨行业发展及趋势；同时，不断完善全球客户体验流程，多角度全方位触达潜在客户并实现高效转化，挖掘生态系统内产品的交叉销售机会。财务表现稳健，盈利持续增长2022年上半年，复锐医疗科技期内实现收入174.5百万美元，同比增长39.3%。该增长主要归因于集团继续扩展现有销售网络，成功推出新产品及拓展了B2C新业务。期内，归母净利润为20.6百万美元，同比增长25.9%。期内，由于集团进一步扩大直销布局及向市场推出高价值产品，集团的毛利由2021年同期的71.5百万美元增加39.4%至99.6百万美元。期内直销产生的收入占总收入的64.8%，分销收入占总收入的35.2%。期内，集团实现税前利润23.1百万美元，净利润20.5百万美元，同比分别增长14.6%及18.2%，该增加得益于销量增加及毛利提升。期内，集团实现经调整净利润24.9百万美元，同比增加27.5%。全球各区域稳步增长，生态品牌进一步加强作为一家跨国企业，复锐医疗科技在推广全球生态品牌的同时，亦着力实现本土化运营以适应当地发展。受益于此，期内，全球各地市场的收益均大幅增长，其中北美区域收入同比增长42.2%，亚太区域同比增长42.0%，中东和非洲同比增长40.5%，拉丁美洲同比增长38.2%，欧洲同比增长28.9%。在多元化生态产品组合方面，通过研发投入，持续推出新技术新产品。通过直营网络布局，在提供优质高价值产品服务的同时，快速收集客户需求，与研发端形成高效闭环，扩充科学医美的产品组合与解决方案，更好满足不同区域客户的医美需求，增强生态品牌竞争力。2022年下半年展望2022年下半年，复锐医疗科技将继续重点发力于新兴技术研发及实践，对内着力于挖掘板块间协同效应，对外放眼于优质业务拓展机遇，以进一步巩固其全球领先地位。2022年，集团的工作将战略性地聚焦精益革新，并进一步加强数字化建设、美丽健康生态系统建设等。秉承“提高生活品质”的企业愿景，集团将继续通过加强全球直销布局，进一步巩固及开拓北美、亚太、欧洲和中东的潜在直营机会，助力复锐医疗科技成为全球化美丽健康集团。此外，集团将继续重视由内而外的健康与美丽需求，进一步拓展能量源设备产品组合，并继续于中国等区域推进注射填充及美容牙科产品的研发拓展。展望未来，复锐医疗科技董事长兼执行董事刘毅先生表示：“复锐医疗科技始终坚持以客户为中心的理念，为广大求美者提供科学有效的美丽健康服务。回顾上半年，复锐医疗科技不断夯实全球化布局，战略部署有序推进。展望下半年，我们将继续践行集团使命，强化四大业务板块协同发展，持续为客户提供多元化美丽健康解决方案，使美丽健康生态系统更具全球竞争力，使科学医美的产品与服务让更多客户受益。”复锐医疗科技及Alma首席执行官Lior Dayan先生表示：“2022年上半年，我们加大了产能投入以适应全球需求的增长。下半年我们将通过战略性地内生与外延协同发力，加大投资引入与合作，配合生态系统搭建战略，从而进一步实现研发能力提升、产品组合扩大及销售渠道扩张。”电话会议公司将于北京时间8月22日（星期一）举行中期业绩发布电话会议（中文场），若您欲参与，请点击以下链接进行登记：https://AlmaLasers.activetrail.biz/Sisram-IR-form. 完成登记后，您将即刻收到拨入信息。为防止延误，我们建议您于会前十五分钟拨入。您亦可登陆复锐医疗科技官网查阅回放记录：https://sisram-medical.com/investors/events-presentations/.  关于复锐医疗科技复锐医疗科技有限公司（股份代号：1696.HK）是一家全球化美丽健康集团，其独特的美丽健康生态系统提供多元化产品组合，打造以客户为中心的品牌，业务包括能量源医美设备、注射填充、美容及数字牙科、个人护理等。复锐医疗科技是中国领先的医疗健康产业集团复星医药的控股子公司。复锐医疗科技于2017年9月19日在中国香港上市，是第一家在香港联合交易所主板上市的以色列公司。复锐医疗科技——提高生活品质https://sisram-medical.com/ Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

15 7 月, 2022

贝康医疗与海尔生物强强联合，构建辅助生殖低温保存解决方案

Qingdao, Shandong, China, Jul 14, 2022 - (亚太商讯 via SEAPRWire.com) - 苏州贝康医疗股份有限公司（以下简称“贝康医疗”）与青岛海尔生物医疗股份有限公司（以下简称“海尔生物”）正式签署战略合作协议。双方将就辅助生殖低温冷冻领域开展合作研发，共同为辅助生殖行业提供低温保存解决方案，这也是继贝康医疗与海创母基金资本合作之后的又一次深度产业合作。海尔生物创始人刘占杰博士、海创千峰母基金总经理刘栋、贝康医疗创始人梁波博士等嘉宾共同出席了本次签约活动。战略合作签约仪式海尔生物产品概览贝康医疗智能化冷冻存储系统胚胎实验室、男科实验室和低温存储实验室是辅助生殖领域重要的组成部分，其中，低温冷冻技术作为实施辅助生殖过程中的一项不可或缺的重要技术，已被广泛应用于辅助生殖领域，为有需要的人群实现生育需求和生殖健康提供了保障和希望。2018年《冷冻胚胎保存时限的中国专家共识》指出：冻存胚胎尽可能在5年之内使用，拟再生育的夫妇最长保存和临床使用期限不要超过10年。这意味着目前辅助生殖中心需要长期投入大量的、逐年递增的存储资源，包括存储容器、存储空间和管理、维护工作等。随着不孕不育和高龄产妇人数的增加，生育力保存的需求缺口还在不断扩大，市场潜力巨大。聚焦生育力保存，构建辅助生殖领域低温保存解决方案海尔生物是青岛市首家登录科创板的企业，始于生物医疗低温存储设备的研发、生产和销售，全面推进物联网技术与低温存储技术的融合创新，将基于网络通讯和射频识别技术的物联网软、硬件与自主研发的低温存储产品相结合，使传统存储设备升级为物联网场景方案，以满足临床用血、疫苗接种、生物样本库应用等用户迭代需求，构建物联网科技生态。海尔生物率先打破国外垄断，自主研发掌握超低温制冷核心技术，成为全球唯一覆盖-196℃至8℃全温域的生物医疗低温存储设备服务商。贝康医疗作为国内辅助生殖领域第一家IVD产业港交所上市公司，一直秉承“做创新产品”的理念，坚持走合规化研发、注册、报证的道路。早在2015年，贝康医疗便启动了胚胎智能存储设备和管理系统的研发，其自主研发的国产化智能液氮罐（BCT38）和超低温存储仪（BSG800A），为生育力保存的安全性和实验管理的科学性提供保障，预计分别在2022年和2023年获得注册证，其中，BCT38将成为国内首个获得二类医疗器械注册证的智能液氮罐产品。此次战略合作，双方将综合各自的产品、渠道等资源优势，从市场推广、技术支持、合作研发、注册报证等方向，共同构建辅助生殖领域低温保存解决方案，推动生育力保存相关应用场景的全面拓展。以全新的资源共享模式赋能辅助生殖行业的发展，帮助好的产品和技术快速有效地进入临床应用，造福更多患者。关于苏州贝康医疗股份有限公司苏州贝康医疗股份有限公司是中国辅助生殖领域三代试管婴儿临床解决方案提供商，是辅助生殖领域第一家IVD产业上市公司（股票代码：2170.HK），致力于高通量测序技术在生育健康领域的产品研发和临床应用。贝康医疗一直秉承做“创新产品”的理念，坚持走研发、注册和销售的产业化道路，拥有覆盖胚胎检测、男科检测及生育力保存的产品管线。公司自主研发的PGT-A（植入前染色体非整倍体检测）试剂盒获得中国首个“创新医疗器械特别审批”绿色通道，是中国首个获得三类医疗器械注册证的三代试管检测产品，开启了中国辅助生殖领域基因检测试剂盒进入医疗器械监管的“有证时代”。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

9 6 月, 20229 6 月, 2022

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Continuously expanding the scope of potential indications for SN1011 HONG KONG, June 9, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 6 June 2022, an Investigational New Drug application ("IND", for neuromyelitis optica spectrum disorder ("NMOSD")) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the "CDE") of the National Medical Products Administration of China (the "NMPA"). The Company plans to initiate the Phase II clinical study in China upon approval of the present IND. The present IND submission, once granted, will enable the Company to conduct clinical program in China for treatment of NMOSD. SN1011 is the Company's third generation, covalent reversible BTK inhibitor with improved safety, higher selectivity and superior efficacy and for the long-term treatment of systemic lupus erythematous, pemphigus vulgaris, multiple sclerosis, rheumatoid arthritis, and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market in terms of mechanism of action, affinity, selectivity and safety. The Phase I clinical study (first-in-human clinical trial) of SN1011 was conducted in Australia and China in 2019 and completed in July 2021, which has demonstrated improved safety and good pharmacokinetics profile. Currently, the IND application for SN1011 in the treatment of systemic lupus erythematosus (SLE), pemphigus vulgaris (PV) and multiple sclerosis (MS) have been approved by NMPA, the Company plans to launch the Phase II clinical study of SN1011 for pemphigus in the third quarter of 2022. The Company is also planning an IND submission for multiple sclerosis (MS) in the U.S. in the second quarter of 2022, thereby accelerating the initiation of a global phase II trial in the third quarter of 2022. NMOSD is an autoimmune-mediated inflammatory demyelinating disease of the central nervous system with predominant involvement of the optic nerve and spinal cord. The pathogenesis of NMOSD is mainly associated with aquaporin-4 (AQP4) antibodies and is a separate disease entity from multiple sclerosis, with severe optic neuritis and longitudinal extensive transverse myelitis as the main clinical features. However, the cause of NMOSD is unknown, with a combination of environmental factors such as smoking, low vitamin D levels, EBV infection and genetic susceptibility contributing to the development of the disease. In 2020, according to inpatient registration data published in China, the incidence of NMOSD is about 0.278 (100,000 people/year), with children at 0.075 (100,000 people/year) and adults at 0.347 (100,000 people/year). NMOSD is seen at all ages, with young adults being the most common, with the average age of onset being 40 years. NMOSD is a highly recurrent and disabling disease, with 40-60% of patients experiencing a recurrence within one year and 90% within three years, and 50% of patients with a natural course of the disease having severe visual or motor impairment within 5-10 years. Currently, there are only three drugs officially approved by the US FDA or the European Union for the treatment of NMOSD, including complement inhibitors, IL-6 receptor blockers and B-lymphocyte-depleting agents. On 30 April 2021, the NMPA officially approved satralizumab for treatment of AQP4-IgG positive patients over the age of 12 years, making it the first drug approved for NMOSD treatment indications in mainland China. An IND application for NMOSD for SN1011 of SinoMab has been accepted by the CDE of the NMPA, and once approved, will facilitate the clinical research and development of new drugs for NMOSD in China. Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "NOMSD is the fourth indication of SN1011 in China following the approvals of IND application for systemic lupus erythematosus (SLE), pemphigus vulgaris (PV) and multiple sclerosis (MS), and is also the third IND application submitted by the Company to the regulatory authority this year, which fully reflects the team's ability to simultaneously advance the research and development of multiple drug candidates and to effectively execute and communicate. The potential indications for SN1011 continue to expand, BTK inhibitor has a wide range of applications in the field of treatment of autoimmune diseases and huge future market potential. We believe that if the SN1011 product is successfully approved and commercialized in the future, it is expected to bring positive benefits to the Company, provide new options for the treatment of various autoimmune diseases and bring hope to the majority of patients." About SinoMab BioScience Limited SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

7 6 月, 2022

华领医药在2022ADA科学年会公布多格列艾汀能够明显改善2型糖尿病患者和GCK-MODY患者的胰岛素早相分泌和葡萄糖敏感性

SHANGHAI, CHINA, Jun 7, 2022 - (亚太商讯 via SEAPRWire.com) - 华领医药（「公司」，香港联交所股份代号：2552.HK）今天宣布，在第82届美国糖尿病协会（ADA）科学年会上，公司展示了其全球首创新药葡萄糖激酶激活剂（GKA）多格列艾汀（dorzagliatin）的多项临床研究成果。一项针对多格列艾汀两项III期临床研究的事后分析报告表明，多格列艾汀能够明显改善2型糖尿病（T2D）患者的胰岛素早相分泌和葡萄糖敏感性。前中华医学会糖尿病学分会主任委员、现任亚洲糖尿病学会副主席、中日友好医院、DAWN研究领衔研究者杨文英教授和华领团队针对多格列艾汀单药SEED研究（播种研究）以及多格列艾汀与二甲双胍联合用药DAWN研究（黎明研究）的两项III期临床研究结果进行了进一步多重变量逻辑回归分析研究，发现受试者在双盲治疗期后血糖达标情况与早相胰岛素分泌指数和处置指数等β细胞分泌功能的关键指标的改善显著相关。进而说明，多格列艾汀作为全球首创的GKA类药物，能够修复T2D患者受损的葡萄糖激酶（GK）的葡萄糖传感器功能，改善胰岛素早相分泌和葡萄糖敏感性，系统提升胰岛β细胞功能，从而恢复T2D患者自主调控血糖的能力，促进了T2D患者的糖化血红蛋白水平达标（HbA1c 由中华医学会糖尿病学分会常委、南京市第一医院内分泌科主任马建华教授领导的DREAM研究（逐梦研究）结果也在ADA大会登场，多格列艾汀的糖尿病缓解研究的成果首次在国际学术会议展示，受到与会代表的普遍关注。DREAM研究是由SEED研究的部分研究者发起的非药物干预的观察性临床研究，主要考察完成SEED研究并且血糖达标的患者停用多格列艾汀后，在不服用任何降糖药物的情况下，其后52周的糖尿病缓解情况。研究结果显示，观察期内，受试者52周糖尿病缓解率为65.2%，糖化血红蛋白、空腹血糖（FPG）和餐后两小时血糖（2h-PPG）水平持续得到控制，β细胞功能维持稳定。研究表明，在新诊断未用药患者中，多格列艾汀能够迅速恢复胰岛素早相分泌和持久改善β细胞功能，有望成为实现糖尿病缓解的重要途径。另一项名为SENSITIZE的临床研究成果同样提供了多格列艾汀在改善胰岛素分泌和葡萄糖敏感性的临床科学数据。该研究由国际内分泌专家、香港中文大学Juliana Chan教授作为研究者发起，探索多格列艾汀对初发2型糖尿病和葡萄糖激酶单基因遗传突变糖尿病 (GCK-MODY或MODY-2)患者的影响。此次ADA科学年会也是SENSITIZE研究结果的首次公开发布。研究结果显示，采用葡萄糖钳夹技术，多格列艾汀可以显著改善GCK-MODY患者的胰岛素第二时相分泌和葡萄糖敏感性，可以显著改善初发T2D患者的基础胰岛素分泌。作为口头报告的主讲人，SENSITIZE研究者之一、香港中文大学Elaine Chow教授还获得了ADA科学顾问团评选的“临床糖尿病、流行病学和糖尿病并发症类”女性专业网络摘要奖 [Women's Interprofessional Network of the ADA (WIN ADA) abstract award]，以表彰她在SENSITIZE研究以及整个糖尿病研究领域优异成果和重大贡献。多格列艾汀在GCK-MODY这一罕见病患者中的应用潜力获得了国际糖尿病研究领域的关注。“临床糖尿病、流行病学和糖尿病并发症类”摘要奖是WIN ADA奖项的重要组成部分，由临床专家、科学家、教育工作者和公共卫生从业人员以及其他糖尿病专业人员组成的WIN ADA顾问团队评选，用以表彰在糖尿病研究、临床护理、公共卫生、教育和相关领域做出重大贡献的杰出女性。华领医药创始人、首席执行官、首席科学官陈力博士表示：“华领医药在2012年提出用血糖稳态概念开发GKA，其核心就是从糖尿病的根本病因上治疗糖尿病，解决葡萄糖敏感性和胰岛素抵抗的问题。新药创新研究最主要的是概念创新，华领医药历经十年，选择了针对大多数中国糖尿病患者安全有效的用药剂量方案和临床研究方案，实现了GKA的成功开发。ADA科学年会上公布的多项临床研究结果进一步验证了多格列艾汀具有‘修复传感、重塑稳态，从源头上治疗糖尿病’的科学理念，为多格列艾汀单药治疗以及作为基石用药联合其他口服降糖药治疗2型糖尿病，乃至实现早期2型糖尿病患者糖尿病缓解和转归，提供了科学依据，也坚定了华领医药实现糖尿病个性化治疗根治糖尿病的信心。”关于多格列艾汀多格列艾汀(dorzagliatin)是一款在研的全球首创胰腺-肝脏双作用的葡萄糖激酶激活剂，旨在通过恢复2型糖尿病患者的血糖稳态来控制糖尿病渐进性退变性疾病发展。通过修复葡萄糖激酶的葡萄糖传感器功能的缺陷，多格列艾汀具有恢复2型糖尿病患者受损的胰岛素和GLP-1分泌的潜力，有望作为该疾病源头治疗的基石药物。目前，公司已经完成多格列艾汀单药治疗和与二甲双胍联合用药的两项III期注册临床研究，以及与DPP-4抑制剂西格列汀和SGLT-2抑制剂恩格列净的联合用药机制协同性研究。在一项由研究者发起的名为DREAM的研究中，在停用多格列艾汀并且不服用任何其它降糖药物的情况下，研究期内，受试者52周糖尿病缓解率为65.2%。公司已获得由上海市药品监督管理局颁发的多格列艾汀《药品生产许可证》，并已获得国家药品监督管理局的新药上市申请受理，以早日实现多格列艾汀的“全球首创，中国首发”，造福广大糖尿病患者。关于华领华领医药是一家创立于中国的创新药物研发公司，专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。其核心产品多格列艾汀以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，已经在中国完成播种研究(SEED)和黎明研究(DAWN)两项III期注册试验，并已向中国药品监督管理局递交了新药上市申请。这款全球首创的葡萄糖激酶激活剂在临床研究中展示了糖尿病缓解的潜力，以帮助全球数亿糖尿病患者。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

2 6 月, 2022

HG Semiconductor Enters into Cooperation Framework Agreement with China Titans Energy

HONG KONG, Jun 2, 2022 - (ACN Newswire via SEAPRWire.com) - HG Semiconductor Limited ("HG Semiconductor", together with its subsidiaries, "the Group"; stock code: 6908.HK) is pleased to announce that the Group entered into a cooperation framework agreement ("Cooperation Framework Agreement") with China Titans Energy Technology Group Co., Limited ("China Titans Energy"; Stock Code: 2188.HK) on 31 May 2022, to commence a three-year strategic cooperation.China Titans Energy focuses on the development of power electronics, aiming to use advanced technology of power electronics and automation control to address the needs of power transformation, supervision, controlling, optimisation, energy saving and new energy utilization. Pursuant to the Cooperation Framework Agreement, the Group and China Titans Energy intend to cooperate on fast charging pile technology promotion and product sales in Mainland China and Hong Kong, to promote complementarity between the strength of both parties in their respective business areas:i) China Titans Energy will provide support for the Group to build advanced fast charging pile products, run fast charging pile services in Hong Kong and jointly launch fast charging system solutions. Both parties will leverage on the unique advantage of the Group in being in cooperation with a statutory body in Hong Kong, to jointly promote the development of the Hong Kong smart city and provide upgrade to the electric vehicles and charging facilities in Hong Kong, so as to achieve the international standard of 400 kilowatts direct current charging, data on cloud, safety monitoring etc for smart management. The new energy fast charging solution is expected to become a pioneer solution in Hong Kong and will help to create new local business model and investment opportunities, such as constructing vehicle-to-grid (V2G) energy network, distributed energy storage and grid-level direct current electrical substation;ii) both parties will cooperate in research and development of the new generation fast charging piles using the third-generation semiconductor technology provided by the Group; andiii) HG Semiconductor will engage China Titans Energy for the manufacture of, and supply the Group's customers in Mainland China and Hong Kong with, the new generation fast charging piles under the brand of the Group.The "New-Energy Vehicle Industry Development Plan for 2021-2035" under the Fourteen Five-Year Plan of China has deployed five strategic tasks, including i) improving technological innovation capability, ii) constructing a new industrial ecology, iii) promoting industrial integration development, iv) improving the infrastructure system, and v) deepening open cooperation; at the same time the development plan explicitly pointed out the necessity of establishing a technological innovation system with enterprises as the main body, strengthening the infrastructure such as charging and replacing, while the battery management system and batteries are also recognized as one of the key development technologies. Meanwhile, the Hong Kong government also announced the roadmap for the popularization of electric vehicles, aiming to achieve zero emissions for all vehicles by 2050, so that Hong Kong can move towards the vision of zero carbon emissions, clean air and smart city in an orderly manner. In recent years, Hong Kong government has been actively promoting "re-industrialisation" and the development of advanced manufacturing industries based on new technologies and intelligent production, which has injected a steady stream of impetus into the development of the third-generation GaN business in the city. The management of the Group is delighted to have China Titans Energy as its strategic partner to advance the re-industrialisation of Hong Kong's next generation semiconductor industry and the development and construction of smart cities in Hong Kong. The Group has obtained six fast-charging battery system patents in 2021 for charging stations, charging conversion systems, charging modules and fast-charging equipment for electric vehicle charging stations. The Cooperation marks the gradual progress of HG Semiconductor towards the goal of harvesting, providing the Group with the opportunity to commercialize its fast charging battery products under its own brand in Mainland China and Hong Kong, and accelerating the pace of achieving production capacity. With the growing popularity of electric vehicles in Mainland China and Hong Kong, there is a promising business prospect for the development and commercialization of next-generation charging piles in both places. The Group will strive to explore opportunities of establishing a business presence in Hong Kong for fast charging battery solutions and is confident that it will pioneer revolutions and drive new trends within the industry. About HG Semiconductor LimitedHG Semiconductor Limited (6908.HK) is principally engaged in semiconductor product business in China, including the design, development, manufacturing, subcontracting services and sales of light-emitting diode ("LED") beads, new generation of semiconductor gallium nitride ("GaN") chips, GaN components and related application products, as well as fast charging products. Leveraging its industry expertise in LED manufacturing, the Group is dedicated to accelerating its research and development and expansion in the application of GaN related products, with an aim to become a leading semiconductor company with the integration of design, manufacturing and sales of semiconductor chips, as well as providing total solutions with higher efficiency and competitive system cost. For more details, please visit www.hg-semiconductor.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

13 5 月, 2022

祝贺！国际顶级医学期刊《自然-医学》同时发表两篇关于华领医药全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文

SHANGHAI, CHINA, May 13, 2022 - (亚太商讯 via SEAPRWire.com) - 华领医药(“公司”，香港联交所主板股份代号：2552.HK)今日宣布，国际顶级医学刊物《自然-医学》（Nature Medicine）杂志同时在线发表了两篇公司全球首创糖尿病新药葡萄糖激酶激活剂（GKA）多格列艾汀（dorzagliatin）的III期注册临床研究结果的同行评议论文。两篇论文分别详细展示和描述了多格列艾汀单药（SEED研究）用于治疗新诊断未用药2型糖尿病患者，以及多格列艾汀联合二甲双胍（DAWN研究）用于治疗二甲双胍足量治疗失效2型糖尿病患者的临床疗效和安全特征。葡萄糖激酶激活剂的III期临床研究成果首次发表在《自然-医学》杂志，代表中国大型注册临床研究成果开始走上国际舞台。多格列艾汀是全球首次完成2型糖尿病III期注册临床研究的GKA类原创新药，由中国研究者领导开发。两篇论文也是《自然-医学》杂志首次发表由中国研究者作为第一作者和通讯作者撰写的新机制糖尿病首创新药。两项研究均表明，在对两类2型糖尿病患者的治疗过程中，通过修复葡萄糖激酶（GK）的传感器功能缺陷，多格列艾汀能够持续、有效降低2型糖尿病（T2D）患者的糖化血红蛋白，显著降低餐后两小时血糖，在无低血糖条件下血糖达标率高，具有良好的安全性和耐受性，持续改善β细胞功能和降低胰岛素抵抗。多格列艾汀是华领医药历时10年自主研发的以GK为靶点用于治疗2型糖尿病的全球首创口服新药。GK在维持人体血糖稳态过程中发挥着核心作用，作为葡萄糖传感器感知人体血糖变化，及时刺激控糖器官分泌胰岛素、GLP-1或胰高糖素，有效调控人体血糖水平，将血糖控制在稳态范围之内（4-6.5 mmol/L的葡萄糖区间）。葡萄糖敏感性受损，主要表现为胰岛β细胞的葡萄糖刺激胰岛素分泌（GSIS）功能受损，餐后血糖升高，血糖波动增大，是T2D的源头病因。多格列艾汀作用于胰腺、肝脏、肠道等血糖调控器官的葡萄糖激酶，通过修复T2D患者的GK功能，修复人体对血糖水平变化的敏感性，改善胰岛素早相分泌和β细胞功能，降低血糖波动，重塑血糖稳态，控制和延缓2型糖尿病的进展，实现糖尿病停药缓解。华领医药已经先后发表了10多篇基础研究和临床研究结果方面的论文，不断阐明“修复传感、重塑稳态、从源头治疗糖尿病”的科学概念，《自然-医学》杂志发表的III期研究成果正是对此创新概念的临床验证。2021年3月，华领医药向国家药品监督管理局（NMPA）递交了多格列艾汀用于治疗T2D的新药上市申请，并于4月获得受理。目前，多格列艾汀处于审核冲刺阶段，华领医药正在积极配合NMPA的工作，争取尽快获得该药的新药上市批准。《自然-医学》是《自然》（Nature）旗下专注生物医学领域的学术期刊，重点关注“展示新颖疾病过程的机理，有直接证据的生理相关的研究结果”的原创论文。近年来开始专注发表大型临床研究论文，《自然-医学》的影响因子持续上升，近2年影响因子为53.44，超过《自然》杂志，跻身国际医学杂志前五位之列，其中包括传统四大医学杂志（《新英格兰医学杂志》（NEJM）、《柳叶刀》（Lancet）、《美国医学会杂志》（JAMA）和《英国医学期刊》（BMJ）。2009年葡萄糖激酶之父Franz Matschinsky 在《自然综述-药物发现》杂志首次报告葡萄糖激酶激活剂的研发进展，GKA相关的理论研究和药物研发成果受到国际学术界和临床医学界的广泛重视，多格列艾汀的II期临床研究结果曾发表在高级医学期刊《柳叶刀-糖尿病与内分泌》杂志上，引起国际社会普遍关注。从2014年起，华领医药及其临床专家每年都会在世界上最大、最重要的糖尿病会议——美国糖尿病协会（ADA）科学年会展示多格列艾汀的基础和临床研究结果，《自然-医学》编辑正是通过ADA科学年会关注到多格列艾汀的创新性和突破性，并主动向华领医药提出约稿。此次发表的两篇文章分别呈现了多格列艾汀SEED研究和DAWN研究两项III期临床研究的结果。SEED研究（播种研究）为多格列艾汀单药研究，是在新诊断未用药的T2D患者中进行的随机、双盲、安慰剂对照的III期注册临床研究，在463名T2D患者中开展。前24周为随机、双盲、安慰剂对照治疗期，用以评估试验的主要疗效和安全性终点，后28周为多格列艾汀开放治疗期，用以持续观察和评估多格列艾汀的安全性。SEED研究由中华医学会糖尿病学分会主任委员、南京大学医学院附属鼓楼医院内分泌代谢病医学中心主任朱大龙教授领衔研究。研究结果表明，多格列艾汀可以有效降低新诊断未用药T2D患者的血糖，同时具有良好的安全性和耐受性。SEED研究的主要结论包括：疗效显著并长期持续：-- 24周糖化血红蛋白相对基线降低1.07%，显著优于安慰剂组(p-- 24周糖化血红蛋白达标率为42.5%，显著高于安慰剂组(p-- 显著改善β细胞功能，24周HOMA2-β与安慰剂组相比，增加3.28-- 24周餐后2小时血糖值相对安慰剂组明显降低2.33mmol/L-- 24周空腹血糖值相对安慰剂组明显降低0.33mmol/L-- 52周糖化血红蛋白仍保持持续稳定耐受性和安全性良好：-- 24周内低血糖(-- 52周内低血糖(-- 52周内无药物相关的严重不良事件DAWN研究（黎明研究）为在二甲双胍足量治疗失效的2型糖尿病患者中使用多格列艾汀联合二甲双胍治疗的随机、双盲、安慰剂对照III期注册临床研究，在767例患者中开展。前24周为随机双盲、安慰剂对照治疗期，用以评估试验的主要疗效和安全性终点；后28周为多格列艾汀开放治疗期，用以持续观察和评估多格列艾汀的安全性。DAWN研究由前中华医学会糖尿病学分会主任委员、现任亚洲糖尿病学会副主席、中日友好医院杨文英教授领衔研究。研究结果表明，对于单用二甲双胍无法有效控制血糖的T2D患者，联合多格列艾汀可以有效降低血糖，同时具有良好的安全性和耐受性，DAWN研究的主要结论包括：疗效显著并长期持续：-- 24周糖化血红蛋白相对基线降低1.02%，显著优于安慰剂组(p-- 24周糖化血红蛋白达标率44.4%, 显著高于安慰剂组10.7%(p-- 显著改善β细胞功能，24周HOMA2-β与安慰剂组相比，增加2.43-- 24周餐后2小时血糖值相对安慰剂组明显降低2.48mmol/L -- 24周空腹血糖值相对安慰剂组明显降低0.38mmol/L -- 52周糖化血红蛋白仍保持持续稳定耐受性和安全性良好：-- 24周内低血糖（-- 52周内低血糖（-- 52周无药物相关的严重不良事件SEED研究论文第一作者朱大龙教授表示：“多格列艾汀的研究者团队和华领医药的开发团队始终以患者的临床需求为中心，坚持严谨的科学态度，共同实现了这款全球首创新药的成功开发。两项III期临床研究结果在《自然-医学》杂志的发表，再次证明了国际学术界对中国新药开发能力的认可与肯定。作为一个临床研究者，我感到非常骄傲，也对中国创新药发展的未来充满了信心。在临床试验中，多格列艾汀展现出了长期稳定的疗效和良好的安全性与耐受性，同时，在与SGLT-2抑制剂和DPP-4抑制剂等联合用药试验中也显示出明显增效作用。我非常期待多格列艾汀能够早日成为中国的2型糖尿病患者新的治疗方案。”研究论文共同通讯作者、复旦大学附属中山医院内分泌科主任李小英教授表示：“《自然-医学》是具有高影响因子的顶级期刊，多格列艾汀的临床研究设计始终遵循着国际化跨国公司的标准，正是源于所有研究者和开发者的高标准、高质量的态度，才创造出了具有高价值的突破性药物。对此，我感到非常自豪和激动。2型糖尿病是威胁人类健康的重要疾病，作为临床医生，参与到多格列艾汀的临床研发工作，让我们有机会重新审视人体葡萄糖稳态的调控机制，从而更好地理解2型糖尿病发生发展的过程与特点。”DAWN研究论文第一作者杨文英教授表示：“我感到非常振奋和快乐！多格列艾汀的II期临床研究结果曾登上《柳叶刀-糖尿病与内分泌》，III期临床研究结果又登上《自然-医学》，这样的成就完全可以比肩由跨国药企开发的糖尿病重磅全球首创新药。这是对中国创新药的极大肯定，是对华领医药和陈力博士10年辛勤耕耘的最大回赠，也是我们作为临床研究者最值得回忆的一段经历，有幸遇到这么好的拓荒者，期待多格列艾汀早日上市！”华领医药首席医学官、药品开发部高级副总裁、多格列艾汀临床开发负责人张怡博士表示：“SEED和DAWN两项临床研究结果在《自然-医学》上的发表，充分展示了中国临床研究者的科研能力和华领医药作为中国生物医药公司的创新研发实力。多格列艾汀III期临床研究是GKA类药物在全球范围首次完成的确证性临床研究，也是首个以中国临床团队为主导，以中国受试者为研究对象完成的全球首创糖尿病新药临床研究。非常感谢所有临床研究者的不懈努力和辛勤付出，未来，华领医药有信心携手各临床领域的合作伙伴，在2型糖尿病和整个代谢病领域不断取得新的突破。”华领医药创始人、CEO、首席科学官、两篇论文的通讯作者陈力博士表示：“我们非常高兴与Jennifer Sargent 主编合作，将多格列艾汀的临床研究成果发表在《自然-医学》杂志上，这说明了国际医学界对GK机理和GKA药物的高度关注和重视。1968年，葡萄糖激酶之父Franz Matschinsky教授发现了GK在葡萄糖刺激胰岛素分泌中的核心作用，并提出葡萄糖激酶是糖尿病基因和葡萄糖传感器，积极推进葡萄糖激酶激活剂的药物研发，经历了众多药物研发困难和失败。50多年后，我非常欣慰地看到，经过10年艰苦卓绝的努力，华领医药研发团队和中国临床专家攻坚克难，大大提高了对葡萄糖激酶在血糖稳态调控和糖尿病治疗中的作用机理的认识，建立了全球领先的糖尿病治疗的科学概念，并成功地将其转化为突破性新药多格列艾汀的研发成果。近期发布的SEED治疗跟进DREAM研究（逐梦研究）结果，进一步阐明多格列艾汀能够从源头上治疗糖尿病，实现糖尿病无药缓解的重大科学进展。华领医药正在积极配合NMPA的审批工作，希望能够尽快让这一创新药物造福广大中国2型糖尿病患者。”SEED研究设计播种研究是一项在未接受过糖尿病药物治疗的新诊断2型糖尿病患者中展开的随机、双盲、安慰剂对照的III期注册临床研究，共纳入463位受试者。整个研究历时53周，包括52周治疗和后续1周安全性随访，前24周为随机双盲、安慰剂对照的疗效和安全性研究，受试者以2：1比例入组，随机接受一天两次口服75mg多格列艾汀或安慰剂治疗。后28周为开放性药物治疗的药物安全性研究，所有受试者均接受一天两次口服75mg多格列艾汀进行治疗。该研究由中华医学会糖尿病学分会主任委员、南京大学医学院附属鼓楼医院内分泌科代谢病医学中心主任朱大龙教授领衔，在中国40家临床中心开展。（临床研究登记注册号：NCT03173391）DAWN研究设计黎明研究是一项在二甲双胍足量治疗失效的2型糖尿病患者中使用多格列艾汀联合二甲双胍治疗的随机、双盲、安慰剂对照的III期注册临床研究，共纳入767位受试者。在前24周双盲治疗期内，受试者每天服用1500mg二甲双胍（格华止®）作为基础治疗，并以1:1的比例随机接受每日两次75mg多格列艾汀或安慰剂治疗。后28周为开放治疗期，所有受试者均接受每日两次75mg多格列艾汀及1500mg二甲双胍（格华止®）治疗。该研究由前中华医学会糖尿病学分会主任委员、现任亚洲糖尿病学会副主席、中日友好医院杨文英教授领衔，在中国72家临床中心进行。（临床研究登记注册号：NCT03141073）关于多格列艾汀多格列艾汀(dorzagliatin)是一款在研的全球首创胰腺-肝脏双作用的葡萄糖激酶激活剂，旨在通过恢复2型糖尿病患者的血糖稳态来控制糖尿病渐进性退变性疾病发展。通过修复葡萄糖激酶的葡萄糖传感器功能的缺陷，多格列艾汀具有恢复2型糖尿病患者受损的胰岛素和GLP-1分泌的潜力，有望作为该疾病源头治疗的基石药物。目前，公司已经完成多格列艾汀单药治疗和与二甲双胍联合用药的两项III期注册临床研究，以及与DPP-4抑制剂西格列汀和SGLT-2抑制剂恩格列净的联合用药机制协同性研究。在一项由研究者发起的名为DREAM的研究中，在不服用任何降糖药物的情况下，研究期内，受试者52周糖尿病缓解率为65.2%。公司已获得由上海市药品监督管理局颁发的多格列艾汀《药品生产许可证》，并已获得国家药品监督管理局的新药上市申请受理，以早日实现多格列艾汀的“全球首创，中国首发”，造福广大糖尿病患者。关于华领华领医药是一家创立于中国的创新药物研发公司，专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。其核心产品多格列艾汀以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，已经在中国完成播种研究(SEED)和黎明研究(DAWN)两项III期注册试验，并已向中国药品监督管理局递交了新药上市申请。这款全球首创的葡萄糖激酶激活剂在临床研究中展示了糖尿病缓解的潜力，以帮助全球数亿糖尿病患者。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

12 5 月, 2022

长江电力发挥清洁能源优势开启高质量发展新篇章

BEIJING, CHINA, May 12, 2022 - (亚太商讯 via SEAPRWire.com) - 中国长江电力股份有限公司（以下简称“长江电力”，股票代码600900.SH）2021年度暨2022年第一季度业绩说明会在上证路演中心举办，独立董事张必贻先生、财务总监詹平原先生、董事会秘书薛宁先生等多位高管出席了业绩说明会，就公司业绩成果、战略布局、风险管理等问题与投资者、分析师进行了沟通交流。长江电力管理并运行三峡、葛洲坝、溪洛渡、向家坝、乌东德、白鹤滩等6座巨型水电站，是全球最大的水电上市公司。2021年，长江电力所属梯级电站年度累计发电量2,083.22亿千瓦时，超计划完成发电任务；拟每10股派发现金红利8.153元（含税）（人民币，下同）。其中，三峡电站年发电量第三次超千亿千瓦时，葛洲坝电站年发电量再创新高，其代管的两座电站，白鹤滩电站发电155.89亿千瓦时、乌东德电站发电389.72亿千瓦时，为迎峰度冬和电力保供贡献了可观增量。同时，长江电力公告2022年一季度业绩情况，2022年一季度，累计发电量469.6亿千瓦时，同比增长约27%。长江电力成功实现了一季度业绩“开门红”。截至目前，长江电力水电总装机容量4,559.5万千瓦，其中，国内水电装机4,549.5万千瓦，占全国水电装机的11.64%，其代管的乌东德、白鹤滩水电站装机共1,620万千瓦，占全国水电装机的4.14%。资产重组与战略投资并举夯实全球水电巨擘龙头地位2021年11月，长江电力公告启动重大资产重组计划，拟注入乌东德电站、白鹤滩电站，截至目前相关工作正在有序推进。乌东德电站、白鹤滩电站全部注入后，长江电力可通过长江流域的六座巨型水电站实现“六库联调”，将大幅提升其水电装机量和流域梯级联合调度能力，为下游带来可观的节水增发电量，进一步巩固长江电力全球水电巨擘的龙头地位。在做强水电主业的同时，长江电力积极开展产业链上下游和相关新兴领域战略投资，2021年实现投资收益54.26亿元，创历史新高，实现公司收益有效增厚。同时，借助大水电运维核心能力，有序推进金沙江下游风光水储一体化可再生能源开发，利用水风光互补形式布局推进抽水蓄能业务的发展，创新推进智慧综合能源、城市绿色综合能源管家模式，积极布局“源网荷储”一体化发展。目前，长电新能公司已注册成立，在积极推进金沙江下游水风光一体化基地的开发和水风光互补的运行调度研究。长江电力现已获取了内蒙古固阳“源网荷储”等一批大基地项目，并锁定了甘肃张掖盘道山、重庆涪陵太和等抽水蓄能和新能源项目。审慎推进国际化拓展向世界一流清洁能源上市公司迈进做大做强国内业务的同时，长江电力继续向国际拓展。2021年，长江电力顺利完成秘鲁路德斯公司项目强制要约收购工作，克服疫情影响向秘鲁派驻第二批现场管控团队，完成调整董事会构成，增加外籍董事等管理任务。同时亦围绕主业积极获取境外资源。积极参与国际大坝委员会、国际能源署等国际交流，长江电力国际影响力持续提升。2021年，长江电力首获穆迪“ A1 ”国家主权级评级，市值首破5,000亿，最高达5,237亿元，稳居中国 A 股电力板块首位、全球电力上市公司前列；富时罗素 ESG（是侧重于关注企业环境、社会、公司治理的评价标准）排名位居国内 A 股电力行业第一。在备受国际市场认可的被背后，长江电力亦成功发行国内首批可持续发展挂钩债券；圆满完成 2016 年境外双币种可交换债券到期兑付，实现高效盘活存量金融资产。致力于绿色可持续发展巩固拓展脱贫攻坚成果水电是可再生的清洁能源，长江电力作为全球最大的水电上市公司，装机容量约占中国水电总装机的 11.64%。2021年，长江电力梯级水电站共生产2,083.22亿千瓦时的清洁电能，与燃煤发电相比，相当于替代标准煤约6,351.74万吨，减少二氧化碳排放约17,332.39万吨，减少二氧化硫排放约3.33万吨，减少氮氧化物排放约3.73万吨，为保护生态、防治污染、防止雾霾和气候变暖奉献了卓越力量。长江电力亦绿色可持续发展，注重发挥水电站的生态环保综合效益，在保护生物多样性、“生态调度”改善水生态环境、“补水调度”为下游提供生态补水等方面也做出了积极贡献。值得一提的是，长江电力结合大水电行业涉及移民多、偏远贫困地区多、与电站生产秩序关系密切等特点，根据国家相关要求和部署，持续加强对定点帮扶县和电站库坝区的支持帮扶力度，全年实施履责项目60项，投入资金2.37 亿元，推进帮扶地区产业、教育、医疗、生态等全面振兴。其中，在武汉市口腔医院实施的“幸福微笑”公益项目，资助困难家庭唇腭裂儿童开展修复手术，助力特殊儿童改变命运，能够“微笑”面对生活。关于长江电力中国长江电力股份有限公司是经国务院批准，由中国长江三峡集团有限公司作为主发起人设立的股份有限公司。公司创立于 2002 年 9月 29 日，2003年 11 月在上交所 IPO 挂牌上市，股票代码 600900，现有股份 227.4 亿股。2020 年 9 月30 日，公司所发行的“沪伦通”全球存托凭证在英国伦交所上市交易。长江电力主要从事水力发电、配售电、智慧综合能源及投融资等业务，在中国、葡萄牙、秘鲁、巴西、巴基斯坦等多个国家开展相关业务。长江电力现拥有长江干流三峡、葛洲坝、溪洛渡和向家坝4座电站的全部发电资产，总装机容量 4,559.5 万千瓦（未含目前受托管理的乌东德电站和白鹤滩电站），其中国内水电装机 4,549.5万千瓦，占全国水电装机总量的 11.6%，权益装机 1,000万千瓦，是中国最大的电力上市公司和全球最大的水电上市公司。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

25 4 月, 2022

G3 Global Berhad and China Partners Remain Committed to Furthering Malaysia’s Digital Economy Blueprint

KUALA LUMPUR, Apr 25, 2022 - (ACN Newswire via SEAPRWire.com) - G3 Global Berhad (G3 or the Company), a developer of artificial intelligence (AI) and other information technology (IT) - based solutions for various industries, remains committed to the vision of the Memorandum of Understanding (MoU) with SenseTime Group Ltd (SenseTime) and China Harbour Engineering Company Ltd (CHEC) for the development of an AI Park.Dirk Quinten, Managing DirectorThe MoU, which was signed on 26 April 2019, expires today.Managing Director of G3, Mr. Dirk Quinten, said, "G3 will continue to focus on its AI and other IT-based solutions to grow the business. The parties to the MoU noted that the landscape for the development of the originally anticipated AI Park has changed and that the project may have to take on a new form.""G3 as well as SenseTime and CHEC remain keen to work together on large-scale AI & IT projects that are sustainable over the longer term. We have been exploring and discussing concepts that leverage on each other's strengths and expertise, whilst considering Malaysia's AI roadmap and strategic position at the same time."The Company will make the necessary announcements to Bursa Malaysia Securities Berhad as and when there are further developments on these discussions.G3 Global: https://g3global.com.my/G3 Global: 7184 / [BURSA: G3G] [RIC: GLOA:KL] [BBG: G3G:MK] Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

23 4 月, 2022

Annual Report on Form 20-F for Fiscal Year 2021 of Aluminum Corporation of China Limited Now Available

BEIJING, Apr 23, 2022 - (ACN Newswire via SEAPRWire.com) - Aluminum Corporation of China Limited (the "Company"; NYSE "ACH"; SEHK "2600"; SSE "601600") announces that the Company's annual report for the 2021 fiscal year filed with the SEC on April 22, 2022 can be accessed via the following link: http://www.chalco.com.cn/en/report/2021/202204/t20220421_93456.html A hard copy of the Company's complete annual report will be provided to any shareholder without charge upon written request to Aluminum Corporation of China Limited at No. 62 North Xizhimen Street, Haidian District, Beijing, PRC 100082. Background information: Aluminum Corporation of China Limited is a leading enterprise in non-ferrous metal industry in China. The scope of business of the Company primarily includes bauxite and coal mining, alumina refining, primary aluminum smelting, trading of alumina, primary aluminum, other non-ferrous metal products, coal products and raw and ancillary materials in bulk and power generation. The Company was established as a joint stock limited company incorporated in the People's Republic of China. The Company's American Depository Shares and H Shares are listed on the New York Stock Exchange, Inc. and the Stock Exchange of Hong Kong Limited, respectively. The Company's A Shares are listed on the Shanghai Stock Exchange. For further information, please visit http://www.chalco.com.cn Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

20 4 月, 2022

Actual net profit exceeds FY2020’s level, China Biotech Services’ (08037) new growth drivers expected to erupt consecutively

HONG KONG, Apr 20, 2022 - (ACN Newswire via SEAPRWire.com) - As the pandemic continued to affect the market, China Biotech Services (08037), which owns one of the largest nucleic acid testing laboratories in Hong Kong, recently announced its 2021 annual report.According to the annual report, China Biotech Services recorded revenue of HK$624 million and net profit of HK$133 million during the reporting period due to strong demand for nucleic acid testing, as a result of the ongoing epidemic in Hong Kong. Thanks to the overall decline in the cost of materials used for nucleic acid testing, the Company's gross profit margin increased by 5.69 percent to 57.4%.In order to expand the business capabilities of the testing business segment, China Biotech Services increased its expenditure during the reporting period, which, combined with greater R&D investment, placed pressure on its net profit margin. Excluding investments in new product launches and R&D, the Company's actual net profit would have exceeded that of 2020.With the advent of the post-pandemic era in view, the Company's development path has become clearer. While enriching the product pipeline of the testing business and providing diversified testing services to generate stable cash flow, it has strengthened its investment in the latest precision radiotherapy technology and CAR-T innovative drugs to create new growth drivers and laid a solid foundation for the Company's rapid growth in the future and raise its intrinsic value.Precision testing enriches product lines, with channels expanded to accelerate business developmentCommitted to becoming the world's leading integrated platform for cancer treatment, China Biotech Services has formed three business segments, namely precision testing, precision treatment, and all-round precision targeted drug research and development, through both in-house R&D initiatives and patent introduction. The synergistic development of the sectors has continued to enhance the core competitiveness of the platform.Among them, precision testing is the "ballast" for the Company's steady development, not only because it is the main source of income, but also because the profits generated from this business play a key role in the cultivation and incubation of the other two major businesses. In order to ensure the continuous and stable development of the precision testing business in the post-pandemic era, China Biotech Services has made a multi-dimensional layout.Regarding the Sunrise Diagnostic Center (SDC), the fifth wave of the COVID-19 epidemic in Hong Kong has not yet subsided, with around 2,000 new cases reported on this 10th and 11th April. Although the peak has passed, the number of infections has not yet dropped to a comfortably low level. Hong Kong Chief Executive Mrs Carrie Lam Cheng Yuet Ngor previously said that universal COVID-19 testing would still be considered if the timing was right.At the same time, SDC offers testing services at a number of major immigration control points. It has been stationed at Hong Kong International Airport, Shenzhen Bay Port and HZMB Hong Kong Port, and offers testing services to China-Hong Kong cross-border drivers. According to the Zhitong Caijing APP, Hong Kong lifted flight bans on nine countries since this 1st April. With the continuous resumption of flights, Hong Kong, as one of the largest airports with the highest passenger flow in the world, will significantly drive the demand for nucleic acid testing. Moreover, the border between Hong Kong and the Mainland is about to open, which will surely drive the demand for nucleic acid testing.In addition to nucleic acid testing, SDC has been cooperating with the government to develop large-scale screening for public health programs including HPV and colorectal cancer, thus expanding the testing product lines. In the meantime, SDC has also made efforts at the service channelfront. In March 2022, it established a joint venture laboratory with Town Health International (03886) to achieve complementary advantages. Through Town Health International's clinic network, SDC's testing services can be quickly introduced to the market and facilitate the sustainable development for theGroup's testing businesses.The Asia Molecular Diagnostic Laboratory (AMDL), which provides cancer precision testing and concomitant diagnostic services, established a strategic partnership with Pillar Biosciences, Inc., a clinical cancer diagnostic company based in Boston, MA and Shanghai, China in 2019. We jointly provide tumor precision diagnostic products and services to Hong Kong, Macau, Great Bay Area, South Korea and Southeast Asia markets, and has built a high-throughput sequencing innovation laboratory at Hong Kong Science & Technology Park.Recently, the laboratory has passed the NGSST-B 2021 (Next-Generation Sequencing Solid Tumor) external quality assessment conducted by the College of American Pathologists ("CAP") with a perfect score. This demonstrates that the laboratory's professionalism and capability in data analysis and interpretation of tumor high-throughput sequencing have reached an advanced international level.Meanwhile, AMDL owns the first & sole commercialization rights of the Pillar Biosciences FDA-approved NGS companion diagnostic (CDx) test for lung and colorectal cancers which guides the prescription of targeted therapies. The CDx test will soon be launched in Hong Kong, where around 37,200 cancer patients seek medical treatment every year, and the demand of cancer diagnostic testing is still rising. Currently, the FDA approved CDx test conducted in Hong Kong are currently sent to the US for test diagnosis, resulting in long-turn around time and high costs (ranging from HK$45,000 to HK$100,000). Moreover, AMDL continues to develop various genetic tests in the fields like tumor mutational burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD) detection and minimal residual disease (MRD) monitoring. As the exclusive test provider and cancer diagnostic products distributor of Pillar Biosciences's FDA approved CDx kits in Hong Kong, AMDL boasts a clear monopolistic advantage. Its upcoming testing services are expected to provide at a reasonable price which aims to provide an accurate and robust cancer diagnostic test service to clinicians and their cancer patients for appropriate targeted therapies. The services are also expected to quickly penetrate the markets in Hong Kong and the Mainland and even the surrounding Southeast Asian markets.With a development history of more than 50 years and high brand recognition, PHC Medical Diagnostic Centre (PHC), one of the largest third-party medical testing centers in Hong Kong, captures a stable market share in traditional testing services. Zhitong Caijing learned that, in addition to introducing the latest WHO-recognized neutralizing antibody test targeting the Omicron variant, PHC has also cooperated with internationally renowned pharmaceutical companies for a contract period of five years to provide testing services for clinical trials. PHC will also continue to contribute stable income and cash flow to theGroup.It is foreseeable that, through the deployment of new growth drivers such as SDC and AMDL, as well as the stable development of PHC, China Biotech Services' precision testing business is expected to grow steadily and continue to play a key role in establishing a solid foundation. BNCT project commences construction, expected to be operational in 2024If precision testing is the main growth driver of current results performance, the boron neutron capture therapy (BNCT) segment is expected to become the new growth driver for China Biotech Services in the medium to long term. It is reported that BNCT therapy, which was introduced from Japan by China Biotech Services, is the world's first BNCT technology to be approved for marketing and inclusion on the National Reimbursement Drug List.Compared with other particle therapies, BNCT therapy can kill tumor cells and tissues with only one radiotherapy treatment, and the course of treatment is significantly shortened. Therefore, the therapy is regarded as a "crown jewel" in the field of radiotherapy and is widely recognized by the industry as a new generation tumor treatment with great development potential.In November 2021, China Biotech Services' BNCT project officially passed the admission assessment of the International Medical Tourism Pilot Zone of Boao Hope City in Hainan, and an agreement for the entry into the pilot zone was signed on 28 February 2022, marking the official commencement of the project's construction. The project is expected to be completed by the end of 2023, and will be ready to start operation and receive patients in 2024.Upon completion, the BNCT Center will become China's first boron neutron treatment facility able to provide commercialized treatment services. It will also become the first cancer center in China to provide BNCT, meeting the BNCT treatment needs of cancer patients nationwide, in Southeast Asia countries and even globally.In terms of market capacity, according to the 2017 Eighth National Radiotherapy Survey Report issued by the (Report of the 8th National Radiation Therapy Survey in 2017) of the Chinese Medical Association, China's radiotherapy equipment was 1.57 units per million people, far less than the 12.4 units per million people in the US, and also falling short of WHO's recommendation of two to four units per million people. Based on 0.5 BNCT devices per 1,000,000 people, the corresponding market demand in China is 700 sets.Compared with 33 proton radiotherapies, BNCT therapy has a higher pricing power thanks to the convenience and safety of only one radiotherapy treatment. The cost of one treatment can be around RMB 300,000 to RMB 400,000, which is still very attractive. Assuming China Biotech Services opens five treatment centers in the future with 10 devices installed and treats 10,000 people a year (in 2020, there were 4.57 million new cancer cases in China and cases of head and neck cancers alone already exceeded 140,000), it can realize an income of RMB 3 to 4 billion in a year, with obvious room for growth.Clinical trials progressing steadily, first subject dosing successfully completed The continued advancement of cell therapy clinical trials has also increased the Group's intrinsic value. On 21 January 2021, the IND application for LY007 Cellular Injection developed by Shanghai Longyao Biotech, a subsidiary of China Biotech Services, was officially approved by the National Medical Products Administration of China. This is the first CD20-targeted chimeric antigen receptor T-cell ("CAR-T") product filed and approved in China. It is reported that LY007 introduces an independent co-stimulatory signaling receptor OX40 into the structure of CAR, which is experimentally proven to reduce T-cell exhaustion, enhance the proliferation and killing ability of CAR-T cells and facilitate the release of more effector molecules, thereby improving the performance of CAR-T in terms of both safety and effectiveness. Given these mechanisms, LY007 has the potential to treat solid tumors, for which the majority of existing CAR-T cell therapies have no significant efficacy.On 25 January and 27 January 2022, the launch event for Phase I registered clinical trial of LY007 for the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma was successfully held at Shanghai Ruijin Hospital and Jiangsu People's Hospital, respectively. The trial is co-hosted by Zhao Weili, Vice President of Ruijin Hospital, and Li Jianyong, Head of the Department of Hematology at Jiangsu People's Hospital.On 1 March 2022, the first subject was enrolled in the LY007 Phase I registered clinical program at Shanghai Ruijin Hospital, and on this 7th April, the infusion of cells for the first subject was completed. The infusion process was generally smooth, and the subject was in good condition following the procedure. The Company expects to compile the preliminary data by the end of September 2022, and the interim data will be released by the first half of 2023. The Phase II clinical trial application is expected to be approved in the first half of next year and will be completed in the second half of 2024, according to China Biotech Services.As we all know, the disclosure of clinical data is a key factor in determining the real value of drug R&D companies. Once the data meet the expectations, the Company's intrinsic value will grow exponentially, and the market has been eagerly awaiting the data of the Phase I clinical trial by Shanghai Longyao Biotech.Moreover, Shanghai Yaolong and the Affiliated Hospital of Xuzhou Medical University officially launched clinical research on an innovative CAR-T (LY011) for treating pancreatic cancer and gastric cancer in October 2021, and four patients have been enrolled. The safety, PK characteristics and preliminary efficacy findings suggest that the LY011 is worthy of further research and development.From the capital market perspective, China Biotech Services has been significantly undervalued. According to data released by China Merchants Securities (Hong Kong), the market value of comparable clinical-stage CAR-T companies listed on main board of The Stock Exchange of Hong Kong is more than US$1.2 billion, while the market value of comparable CAR-T companies listed on NASDAQ is more than US$6 billion. The current market value of China Biotech Services is actually less than US$200 million, which means that the market's perception of China Biotech Services is still limited to precision testing, and the market value only reflects the valuation of the precision testing segment.Nonetheless, China Biotech Services' model of using the profits and cash flow from the testing business to incubate other new growth drivers has proved effective. The BNCT segment and CAR-T cell therapy have been steadily progressing and have become the Company's new growth drivers in the medium to long term, laying a solid foundation for sustainable growth in the future. With the implementation of the BNCT project and the announcement of the clinical trial of the LY007 injection, the intrinsic value of China Biotech Services will be greatly enhanced and is expected to be reflected in its market value, and the present moment is probably the best time to formulate a development plan.In addition, China Biotech Services has achieved profitability for two consecutive years. According to its current operating trend, its performance is expected to maintain stable growth. After achieving profitability this year, the factors restricting the transfer of its listing to the main board will be eliminated, and the Company's financial position will meet the conditions required for the transfer of its listing from the GEM to the main board. Once the transfer is successful, the increase in liquidity will lead to a restoration in valuation. At that time, the Company's market value is expected to rise sharply under the allocation of passive investment funds, and the valuation is expected to be on a par with comparable companies.Source: Zhitong Caijing Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

20 4 月, 2022

Everbright Environment Tops Brand Value Ranking for China’s Listed Environmental Protection Companies

HONG KONG, Apr 20, 2022 - (ACN Newswire via SEAPRWire.com) - The "Blue Book on Brand Value of Chinese Listed Companies 2021" (the "Blue Book") was recently published by the mainland China publication National Business Daily in collaboration with the China Business Research Centre, School of Economics and Management, Tsinghua University. The brand value ranking of the listed companies in China's environmental protection industry was also revealed in the Blue Book. China Everbright Environment Group Limited ("Everbright Environment" or the "Company") (SEHK: 257) topped the list with a brand value of RMB14.622 billion - the only listed environmental protection company with a brand value of over RMB10 billion. Not only does the Company have a brand value that exceeds the sum of the companies ranked second to fifth, but it also has an annual growth rate of 47.3% (compared to the overall industry growth rate of 14.5%), highlighting its status as the leading player in the industry. Everbright Environment is a leading enterprise in China's environmental industry and the first one-stop integrated environmental solution provider in China. The Company focuses on the four major areas of environment, resources, energy and climate. Its main businesses cover a wide range of industry chains and sub-sectors, including waste-to-energy and integrated waste treatment, integrated biomass utilisation, hazardous and solid waste treatment, water environment management, equipment manufacturing, research and development relating to green technologies, and ecological and environmental planning and designing. In 2021, despite the challenging business environment caused by a resurgence of the COVID-19 pandemic and fierce competition, Everbright Environment maintained a steady pace of development and continued to strengthen its position in the industry. The Company's brand influence at home and abroad has been further enhanced through its operating results, industry-leading technological innovation, proactive deployment of low-carbon transformation, continued development of quality projects, exemplary cooperation under the Belt and Road initiative, reputable corporate governance, and continued commitment to social responsibility. Branding is playing an increasingly important role as the core competency of the Company.In 2021, Everbright Environment was shortlisted on the Fortune China 500 list for the first time, ranking in 283rd place. Meanwhile, the Company has been ranked first on the list of China's Top 50 Environmental Enterprises for three consecutive years and ranked first in the "Top Ten Influential Solid Waste Treatment Enterprises in China" for 11 consecutive years. In addition, Everbright Environment was included in the Dow Jones Sustainability Indices for the 6th consecutive year and Hang Seng Corporate Sustainability Benchmark Index for the 11th consecutive year. The Company also received the "Best Environmental Responsibility" award for three consecutive years and was selected as a constituent of the FTSE4Good Index for five consecutive years. Everbright Environment was also named the "Social Responsibility Brand of the Year" by the China Charity Festival for seven consecutive years. The Blue Book also mentioned that with the support of the national "Dual Carbon" strategy and policies related to the in-depth development of the prevention and control of pollution, the environmental protection industry has entered rapid development during the 14th Five-year Plan period and is becoming a vital part in China's industrial structure and economic transformation. The brand value of environmental protection enterprises also has a broad scope for growth, and enterprises need to continuously improve their independent innovation capabilities, forge a more solid brand value, and make more contributions to the green, low-carbon and sustainable development efforts of China and the world.About China Everbright Environment Group LimitedChina Everbright Environment Group Limited ("Everbright Environment") is a backbone enterprise of China Everbright Group Ltd. Everbright Environment is listed on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX") (257.HK). It has two listed subsidiary companies: China Everbright Water Limited, which is dual listed on Singapore Exchange Securities Trading Limited and HKEX (U9E.SG and 1857.HK), and China Everbright Greentech Limited, which is listed on HKEX (1257.HK). Since shifting its business focus to the environmental sector in 2003, the Company has grown into the largest environmental enterprise in China, a leading player in Asia's environmental protection industry, the world's largest waste-to-energy investor and operator, and a world-renowned environmental group. Everbright Environment gains the recognitions of ranking the top among the "Top Ten Influential Solid Waste Treatment Enterprises in China" for 11 consecutive years, the top on the list of China's Top 50 Environmental Enterprises for three consecutive years, and being included in the MSCI China Index for nine consecutive years. Its main businesses cover waste-to-energy and integrated waste treatment, integrated biomass utilisation, hazardous and solid waste treatment, environmental remediation, water environment management, equipment manufacturing, waste sorting, environmental sanitation integration, resource recycling, development of zero-waste cities, energy-saving lighting, analysis and testing, research and development relating to green technologies, ecological and environmental planning and designing, as well as environmental protection industrial parks. The Company has a business presence in more than 210 locations across 25 provinces, municipalities, autonomous regions and special administrative region in China, as well as overseas markets including Germany, Poland, Vietnam and Mauritius. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

29 3 月, 2022

Yeahka to Announce 2021 Annual Results on 31 March 2022, Actively Covered by 13 Leading Brokerages

HONG KONG, Mar 29, 2022 - (ACN Newswire via SEAPRWire.com) - Industrial Securities initiated coverage on Yeahka Limited ("Yeahka" or the "Company") (09923.HK) with an "Overweight" rating. Since 2021, Yeahka has been covered actively by 13 leading brokerages (by alphabetic order), including China Renaissance, China Securities, CICC, CITI, CLSA, Daiwa, Essence Securities, Guosheng Securities, Guotai Junan Securities, Huatai Securities, Industrial Securities, Jefferies, and Zhongtai Securities.Yeahka's sustainable, solid growth is the key to the attention from these brokerages. Recently, Yeahka stated that it will announce its audited consolidated results for the year ended 31 December, 2021.The Company's management will host an earnings conference call on 31 March, 2022 at 8:00 PM Beijing Time (8:00 AM U.S. Eastern Time). Dial-in details for the earnings conference call are as follows:Mainland China: 400 820 6895Hong Kong, China: +852 3018 8307U.S.: 1833 239 5575 (Toll Free) / +1 332 208 9458U.K.: 0800 279 8053 (Toll Free) / +44 203 692 8123International: +65 6780 1201Passcode: 3779473About YEAHKA LIMITED (Stock Code: 9923.HK)Yeahka Limited is a leading payment-based technology platform. Yeahka's vision is to build an independent and scalable commercial digitalized ecosystem. Yeahka seamlessly connects merchants and consumers through payment services of different kinds, including QR code and traditional bank card payment. In addition, Yeahka provides merchant solutions including SaaS digital solutions, precision marketing services, and fintech services to help merchants better manage and drive business growth. On consumer front, Yeahka officially launched in-store e-commerce services in 2021, providing consumers with one-stop local lifestyle services of great value, and a more enjoyable lifestyle. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

22 3 月, 2022

Nissin Foods Announces 2021 Annual Results, Financial Performance Exceeds High 2020 Baseline

HONG KONG, Mar 22, 2022 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods" or the "Company", together with its subsidiaries, the "Group"; Stock code: 1475) has announced its annual results today for the year ended 31 December 2021. Results Highlights-- Revenue increased mainly resulted from high sales volume growth of "Cup Noodles" in Mainland China and an increase in revenue from the diversified portfolio in Hong Kong. -- To celebrate Nissin Foods' 5th listing anniversary in the Stock Exchange of Hong Kong and the 50th birthday of "Cup Noodles", the Board has recommended a final dividend of 14.56 HK cents per share and a special dividend of 2.91 HK cents per share, totalling 17.47 HK cents per share. -- In face of the rising cost pressure from the soaring price of raw materials and logistics, the Group increased the ex-factory price of its key instant noodle products by a mid-single-digit percentage point on average in Mainland China from 1 March 2022. Similarly in Hong Kong, the ex-factory price of certain bag-type and container-type instant noodles will be increased by mid-to-high single-digit percentages from 1 April 2022. Revenue of the Group increased by 9.9% year-on-year ("YoY") to HK3,866.3 million (2020: HK$3,518.8 million). The Group's EBITDA grew by 6.0% YoY to HK$604.1 million (2020: HK$570.0 million), representing an EBITDA margin of 15.6% (2020: 16.2%). Profit attributable to owners of the Company increased by 0.6% YoY to HK$303.8 million (2020: HK$301.9 million), representing a net profit margin of 7.9% (2020: 8.6%). The Group's basic earnings per share increased to 28.74 HK cents for 2021 (2020: 28.11 HK cents) due to a decrease in the weighted average number of shares outstanding attributable to the shares buyback during the year.Hong Kong OperationsRevenue from the Hong Kong operations increased by 3.4% YoY to HK$1,466.2 million (2020: HK$1,418.4 million), due to an increase in revenue from the non-instant noodle business, and in particular, from frozen food, vegetable and fruit juices, fresh-cut vegetables and confectionary, as well as the distribution business in the absence of a demand surge, especially for bag-type instant noodles as experienced in early 2020 when the pandemic began. Segment results amounted to HK$123.5 million (2020: HK$165.5 million). The decrease was mainly attributable to the surge in raw material prices and expenses relating to its brand investments. Revenue from the Hong Kong operations accounted for 37.9% (2020: 40.3%) of the Group's revenue.With relative normalcy returning to Hong Kong for an extended period of time, the performance of the cup-type instant noodles has correspondingly returned to a level achieved in 2020, with solid growth in sales volume realised towards the end of 2021. In celebrating the 50th anniversary of "Cup Noodles" in 2021, the Company has revamped the "Cup Noodles" brand by introducing smoother noodles and improved soup quality; providing excellent dining experiences for its beloved customers. Also, the Company has sustained efforts to offer high-quality noodles under the "Demae Iccho" brand, hence the use of Hokkaido wheat flour which is renowned for its fine texture and fresh wheat flavour, consequently earning high praise from consumers. Moreover, to further complement the instant noodle portfolio, the Company has launched additional offerings under the "Doll" brand, allowing consumers to enjoy a series of novel and innovative products. Outside of its noodle business, the Group's packed fresh-cut vegetables have achieved a steady increase in sales volume. This can be attributed to a rising number of supermarkets now selling the Group's produce, as well as its increasing popularity among health-conscious consumers who favour fresh vegetables. Also, the sales of granola has risen, not only in Hong Kong and Mainland China, but also in Singapore and Thailand. Similarly, the "Kagome" vegetable juice business has been steadily expanding on the back of rising sales volume. Mainland China OperationsRevenue in the Mainland China operations recorded strong growth in the review year, surpassing the high baseline set in 2020. The strong performance is a testament to the effectiveness of its business model, and highlights the Company's commitment to the Mainland China market. Revenue from the Mainland China operations increased by 14.3% YoY (in local currency: 6.6%), rising from HK$2,100.4 million in 2020 to HK$2,400.2 million in 2021, due to sales volume growth by the cup-type instant noodles, as customers continuously gravitated towards new tastes and higher quality products. The joint venture distribution business also contributed to the revenue growth owing to a full year of operation. Segment results significantly increased by 21.0% YoY to HK$299.1 million (2020: HK$247.1 million), mainly attributable to greater sales volume from cup-type instant noodles, but this was offset by the surge in raw material costs. Revenue from the Mainland China operations accounted for 62.1% (2020: 59.7%) of the Group's revenue. Sales volume of Mainland China's flagship "Cup Noodles" brand grew at a double-digit rate. Same as the Hong Kong operations, a product revamp was rolled out in Mainland China - since May 2021, to celebrate the 50th anniversary of "Cup Noodles", which included an upgrade in the quality of noodles and soup. The Company has continuously executed brand investments in its unique instant noodles in Mainland China to build brand loyalty. Along the same lines, the bowl-type Nissin "U.F.O." Stir Noodles was redesigned with an improved lid for draining hot water so as to ensure convenience and safety. Moreover, a new sauce with richer taste was introduced to create a more satisfying consumption experience, hence deliver value added products.Launched in April 2020, the distribution business in Shanghai has been engaging in the distribution of Japanese confectionery and beverages of third-party brands. The subsidiary has also been seeking to expand the sales volume of "Kagome" vegetables and fruit juices, along with the Company's own brand of granola through its sales network. The results were in line with the Company's expectations. Regarding the new packaging materials manufacturing plant located in Zhuhai, as announced in July 2019, its full-scale production commenced in December 2021 after trial operations. The Zhuhai plant primarily produces soft packaging materials, including packaging films for bag-type instant noodles, cup-type instant noodles, liquids, and powders.ProspectsLooking ahead, unless and until the pandemic is contained and daily life returns to normal, raw material price fluctuations will continue to impact the manufacturing businesses for some time. The Company has taken various measures to improve production efficiency and reduce a wide range of costs to alleviate price pressures. However, these measures are insufficient to absorb the constantly rising cost of raw materials. Under this challenging economic environment, the Company increased the ex-factory price of its key instant noodle products in Mainland China by a mid-single-digit percentage point on average from 1 March 2022. This is the first price adjustment in Mainland China in 11 years. Similarly in Hong Kong, the ex-factory price of certain bag-type and container-type instant noodles will be increased by mid-to-high single-digit percentages from 1 April 2022. The price adjustment will be applied to the "Demae Iccho" series, "Cup Noodles" series and "U.F.O." products. The last price adjustment on "Damae Iccho" bag noodles was 14 years ago in 2008, and three years ago in 2019 on container-type noodles, including "Cup Noodles".The Company will continue to focus on expanding its geographical sales coverages and invest in its brands. Consumption is expected to continue to grow in Mainland China, as per capita spending further increases. Nissin Foods is confident in maintaining its track record of sales growth of value-added products and will continue to expand sales coverage, particularly in Northern China and Western China, and increase in-store sales. Meanwhile, the Company will also strive to enhance product quality alongside the price adjustment. In addition, to ensure sustainable growth, the Hong Kong operations will focus on increasing sales from its non-instant noodle business. Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "Amid unprecedented times created by the COVID-19 pandemic, our management, staff and workers have been working together to achieve the management's goals. Consequently, the Group's 2021 financial performance has been able to exceed the high baseline set in 2020. As the consumption upgrade trend remains in progress in Mainland China, there will be ample opportunities for our premium instant noodles to capture greater market share. In terms of the non-instant noodles business, the Group will continue to expand its presence in Hong Kong and Mainland China, create synergies with the noodle business, and thereby enhance the financial performance of this business segment."The challenges brought about by COVID-19 have affected not only our lives, but also our economy and society. As the leading instant noodle manufacturer in Hong Kong, Nissin Foods is committed to providing consumers with quality instant noodles and ensuring their stable supply at all times. We will continue to pay close attention to market changes and adjust our production and logistics support as needed so as to continue to provide consumers with quality and safe products. Going forward, we are determined to maximise business outcome while developing the Group's business operation and organisation, with the aim of creating long-term value for all stakeholders, including shareholders and investors of the Company."For complete information on the Group's 2021 annual results, please refer to the Company's Annual Results Announcement, which is available on the Hong Kong Stock Exchange website at: https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0322/2022032200459.pdf About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the "ECO Cup" concept and primarily focuses its sales efforts in first-and second-tier cities. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

17 3 月, 2022

华领医药公布2021年全年业绩

SHANGHAI, CHINA, Mar 17, 2022 - (亚太商讯 via SEAPRWire.com) - 华领医药（「公司」，香港联交所股份代号：2552），今天宣布公司及其附属公司截至2021年12月31日止，经审核的全年业绩（「报告期」）。报告期内，公司在推动商业化进程中取得里程碑进展，向国家药品监督管理局（NMPA）递交的多格列艾汀（dorzagliatin）用于治疗2型糖尿病的新药上市申请（NDA）获得受理，公司也在积极推进药品全生命周期管理计划。 2021年度，公司开支总额约为人民币3.272亿元，其中研发开支约为人民币1.868亿元。截至2021年12月31日，公司银行结余及现金约为人民币6.752亿元。华领医药始终着眼于未被满足的临床需求，经过10年探索，成功开发出了多格列艾汀这款葡萄糖激酶激活剂类2型糖尿病全球首创新药，实现了从血糖稳态调控的科学理论到全新机制创新药物「从0到1」的突破。近年来，以血糖稳态调控作为理论支持，用于治疗糖尿病及其并发症的新药研发逐渐升温，依托「修复传感，重塑稳态，从源头上治疗糖尿病」的科学理念，多格列艾汀有望成为在中国首先上市的全球首创新药。此外，多格列艾汀还在临床研究中展现出口服用药在糖尿病缓解方面的潜力。 2021年9月公布的DREAM研究结果显示，多格列艾汀在早期血糖控制达目标糖尿病患者中实现了一年内65.2%的糖尿病缓解率。通过在糖尿病患者发病早期实现糖尿病缓解，多格列艾汀有望控制或推迟糖尿病并发症的发生和发展，为其导致的医疗负担和相关社会问题寻找可行的解决方案。目前，多格列艾汀的新药上市申请处于审核阶段，华领医药正在积极配合NMPA的工作，争取尽快获得多格列艾汀的新药上市批准。公司将继续加强与全球医药巨头、中国领先的糖尿病治疗企业拜耳的合作，同时携手药明康德、国药控股、迪赛诺、瑞博制药等生产和供应链合作伙伴，共同推进多格列艾汀的稳定生产、充足供应和市场推广。公司还将继续拓展多格列艾汀在欧美日市场、东南亚市场和「一带一路」市场的发展机遇，实现创新的价值。未来，公司还将探索建立慢病管理平台，通过大数据、人工智能等手段，对患者进行科学管理，开拓慢病管理的新局面。华领医药创始人、CEO、首席科学官陈力博士表示：「2021年是华领医药实现突破性发展的一年，公司核心产品多格列艾汀成为全球范围内首个提交新药上市申请的葡萄糖激酶激活剂类糖尿病治疗药物。多格列艾汀是一款具有新概念、新机理、新疗效、新结构、新技术的『五新药物』，有望通过『源头+周边』治疗的糖尿病管理新概念，实现糖尿病的有效控制和转归。我们期待多格列艾汀能够尽快获批上市，造福广大2型糖尿病患者。华领医药将为中国国民的健康发展继续探索，支持『健康中国2030』关于糖尿病等重大疾病防控的国家战略，实现糖尿病的个性化治疗。」临床研究进展-- 2021年3月，公司向NMPA递交了多格列艾汀用于治疗2型糖尿病的新药上市申请，并于4月获得受理，目前，正处于审核阶段。-- 2021年9月，在第六届中国医药创新与投资大会上，DREAM研究的主要研究者公布了该临床研究的结果。 DREAM研究主要考察参与SEED（播种研究）的患者血糖达标后，在不服用任何降糖药物、仅采用生活方式干预的情况下，其后至少52周的糖尿病控制情况，观察其糖化血红蛋白（HbA1c）能否维持在正常或接近正常水平，以探索多格列艾汀对于糖尿病缓解的作用。研究结果显示，研究期内，受试者52周糖尿病缓解率为65.2%（使用生存分析法计算）。-- 在2021年美国糖尿病协会（ADA）科学年会在线会议上，公司公布了两项III期注册临床SEED（播种研究）和DAWN（黎明研究）的52周研究数据。公司还公布了I期临床研究HMM0112的研究数据，该研究为多格列艾汀与恩格列净（一种SGLT-2抑制剂）联合用药研究，研究结果显示，联合用药在血糖控制方面具有协同增效作用。-- 在2021年美国糖尿病协会（ADA）科学年会在线会议上，公司公布了I期临床研究HMM0111的进一步研究数据。该研究为多格列艾汀与西格列汀（一种DPP-4抑制剂）联合用药研究，研究结果显示，联合用药能够调控GLP-1分泌，在美国2型糖尿病患者的血糖控制方面具有协同增效作用。公司运营进展-- 在推进多格列艾汀的商业化进程方面，公司继续与在中国的商业化伙伴拜耳合作，制定上市战略，做好商业化准备。-- 2021年9月，公司与国药控股股份有限公司（1099.HK）签署供应链战略合作协议，在物流仓储、供应链管理和渠道信息化等方面展开深入合作，共同推进多格列艾汀在中国获批上市后的商业化进程。-- 2021年10月，公司与药明康德子公司合全药业签订商业化生产合作扩大协议，以加深关于多格列艾汀商业化供应方面的既有合作。 2022年2月，双方举行签约仪式并宣布了该协议。-- 在上海临港新片区成立华领医药制药公司，以确保多格列艾汀充足的商业供应，公司已获得用于建设生产的土地。-- 继续围绕公司在葡萄糖激酶方面的科学发现，在全球范围内提交和申请知识产权，包括与多格列艾汀固定剂量复方制剂和第二代葡萄糖激酶激活剂。财务摘要截至2021年12月31日止，年度-- 银行结余及现金为约人民币6.752亿元。-- 开支总额约人民币3.272亿元，其中研发开支约人民币1.868亿元，研发开支减少约人民币3410万元，减幅约15%。-- 税前亏损约人民币3.257亿元，减少约人民币6740万元，减幅约17%。-- 年内亏损及全面开支总额约人民币3.253亿元，减少约人民币6830万元，减幅约17%。业务展望-- 积极配合NMPA的工作，以尽快获得多格列艾汀的新药上市批准。如获得批准，公司将与合作伙伴拜耳在中国共同推进多格列艾汀的商业化，并且争取进入国家医保目录，扩大多格列艾汀作为基石药物，用于单药治疗或与现有其他降糖药物联合使用治疗2型糖尿病的用药前景。-- 计划在2022年公布SENSITIZE研究的结果。-- 计划在美国启动多格列艾汀针对1型糖尿病的临床试验。-- 推进多格列艾汀固定剂量复方制剂和第二代葡萄糖激酶激活剂的开发。关于多格列艾汀多格列艾汀（dorzagliatin）是一款在研的全球首创双作用的葡萄糖激酶激活剂，旨在通过恢复2型糖尿病患者的血糖稳态来控制糖尿病渐进性退变性疾病发展。通过修复葡萄糖激酶的葡萄糖传感器功能的缺陷，多格列艾汀具有恢复2型糖尿病患者受损的胰岛素和GLP-1分泌的潜力，有望作为该疾病源头治疗的基石药物。目前，公司已经完成多格列艾汀单药治疗和与二甲双胍联合用药的两项III期注册临床研究，以及与DPP-4抑制剂西格列汀和SGLT-2抑制剂恩格列净的联合用药机制协同性研究。基于多格列艾汀单药治疗SEED研究的结果，在一项由研究者发起的名为DREAM的研究中，在不服用任何降糖药物的情况下，研究期内，受试者52周糖尿病缓解率为65.2%。公司已获得由上海市药品监督管理局颁发的多格列艾汀《药品生产许可证》，并已获得国家药品监督管理局的新药上市申请受理，以早日实现多格列艾汀的「全球首创，中国首发」，造福广大糖尿病患者。关于华领华领医药是一家创立于中国的创新药物研发公司，专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。其核心产品多格列艾汀以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，已经在中国完成播种研究（SEED）和黎明研究（DAWN）两项III期注册试验，并已向中国药品监督管理局递交了新药上市申请。这款全球首创的葡萄糖激酶激活剂在临床研究中展示了糖尿病缓解的潜力，以帮助全球数亿糖尿病患者。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

16 3 月, 2022

CCMGT Outperformed Four Core Operational Indicators for 2021, Net Profit and Revenue Increased 13%, Dividend Payout Ratio Reached 65%

HONG KONG, Mar 16, 2022 - (ACN Newswire via SEAPRWire.com) - CENTRAL CHINA MANAGEMENT COMPANY LIMITED ("CCMGT" or the "Company", stock code: 9982.HK), a leading property project management company in China, announces its annual results for the 12 months ended 31 December 2021 (the "Reporting Period"). Benefited from the fact that China achieved economic growth, continuous improvement in the management standards of property developers in China and the "Greater Central China" strategy of the Company, the revenue of the Company increased 13.0% to RMB1,300 million as compared to 2020. Net profit amounted to RMB770 million, representing an increase of 13.0% as compared with the last year. Net profit margin was 59.2%. The earnings per share increased RMB1.42 cents to RMB24.39 cents. The Board of Directors declared a final dividend of HK9.90 cents (equivalent to RMB8.09 cents) per share for the year ended 31 December 2021.During the last year, CCMGT was rooted in the Greater Central China region and the Company continued to improve comprehensive capabilities, increase brand influence, consolidate presence in Henan, and grow the Group's confidence. During the Reporting Period, guided by the "Greater Central China" strategy, the Group had 261 projects under management in 119 cities and counties, including 100 cities and counties in Henan and 19 cities and counties in provinces other than Henan, which cover 8 provinces, including Henan, Anhui, Shanxi, Shaanxi, Hebei, Jiangsu, Shandong and Hubei with a population of 430 million. The GDP in the region accounts for 1/4 of the total in China. The Group had an aggregate GFA of 30.97 million sq.m, representing an increase of 21.3% as compared with the last year. During the Reporting Period, the Company had a newly contracted GFA of 10,020,000 sq.m, a year-on-year increase of 16.8%, which included the projects under management were those in provinces other than Henan with GFA of 2.59 million sq.m., an increase of 95.6% as compared with 2020. In addition, the total investment in property development in China amounted to RMB14.7602 trillion in 2021, representing a year-on-year increase of 4.4%. The sales of commercial property grew 4.8% year on year to RMB18.2 trillion. In the context of financing control with "three lines, four levels" and fading of benefits from urbanisation, fault tolerance in the industry has been reduced. The property developers pursued stability and safety. The management standards of property developers will continuously improve.With the asset-light business model of CCMGT, the Company has been adhering to the cooperation philosophy of "Alignment in Culture, Strategy, Standard and Execution". The Company's main businesses currently include commercial project management, government project management, capital project management, and special management consulting services. CCMGT proactively advanced investment in projects in the Greater Central China region. All employees were responsible for marketing and the Company put forward the innovative idea of "graded marketing" to help achieve marketing goals. During the Reporting Period, CCMGT outperformed four core operational indicators, namely investment expansion, contracted sales, management service fees and net profit.Mr. Wu Po Sum, Chairman and non-executive Director of CENTRAL CHINA MANAGEMENT COMPANY LIMITED, said, "China's economy came to a steady end in the tough year of 2021 and this creates a positive, favourable environment for businesses to grow. Moreover, with the release of the State Council's "Guideline on Promoting High-quality Development of the Country's Central Region in the New Era" in 2021 and other related policies, a large number of national strategies unleashed the benefits and huge market demands in the Greater Central China region, which has been the main foundation for the development of the Company. The Greater Central China region is expected to become an important growth driver for China's economy in the future. The Greater Central China region has high population density, fast economic growth, low urbanisation and unbalanced development. Thus, there is enough room for competition and the prospect for development in the future is promising in the project management industry in China."According to China Index Academy, the penetration rate of the project management industry reached 4.8% in 2021. Compared to US and Europe project management industry penetration of 20% to 30%, China's project management industry penetration has room to further grow up to 5.2 times. In addition, according to a Morningstar research distributed by BNP Paribas, the penetration rate of the project management industry will increase to 9% around 2025. Currently, the penetration rate of the project management industry in China is still at a low level.Looking ahead, Mr. Wu Po Sum said, "Currently, the development of the real estate development sector in China is gradually facing limitation. The project management industry, however, has a great potential and promising outlook with high net profit margin. The Group will continue to perform full process fine project management, further enhance management capability, and diversify business models. The Group will also continue to forge core competitiveness, consolidate leading position, and become the leading enterprise in the property management industry. Moreover, the Group will seek common prosperity with more partners and unleash potential in the market, creating greater value for Shareholders."About CENTRAL CHINA MANAGEMENT COMPANY LIMITEDCENTRAL CHINA MANAGEMENT COMPANY LIMITED ("CCMGT" or "Company", Stock code: 9982.HK) is a leading project management company in China with a strategic focus on Greater Central China. Relying on the well-known "Jianye brand", unique asset-light business model, professional project management services, a comprehensive network of high-quality contractors and suppliers, and a set of standardized, high-quality, and continuously optimized and updated "Jianye standards". As a solid foundation for its business, CCMGT continues to help projects create higher value and further consolidate its position as a leading project management company in China. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

19 2 月, 2022

Deloitte fully supports HKSAR government’s fight against COVID-19, donating 100,000 rapid testing kits to aid community response

HONG KONG, CHINA, Feb 19, 2022 - (ACN Newswire via SEAPRWire.com) - With Hong Kong facing an onslaught from the fifth wave of the pandemic, the Deloitte Foundation today launches a program to donate much-needed anti-epidemic supplies to support frontline workers, low-income families, under-privileged children, and the elderly. The Foundation has so far procured over 100,000 COVID-19 rapid testing kits, together with facemasks, hand sanitizers, and disinfection wipes. We are distributing these supplies to frontline workers including the police force, medical workers and the most vulnerable in society directly and through various charities in Hong Kong."As part of the Hong Kong SAR community, we must join forces with the government to work hand in hand to combat this pandemic. We will spare no effort to do what matters most for society during these critical times by leveraging all power and resources, to support the HKSAR government to secure the health and security of all Hong Kong people," says Deloitte China CEO Patrick Tsang.Deloitte China Chairman and Secretary-General of Deloitte Foundation (Hong Kong) Dennis Chow says, "Frontline workers, especially the police force and the medical workers, are carrying out their duties every day under severe conditions. The whole business community is thankful for everything they are doing during this fifth wave, which is putting the healthcare system in Hong Kong under severe pressure. It's only right that we show our appreciation for their efforts and do whatever we can to help Hong Kong through this challenging time.""During these critical and challenging times, Deloitte China and the Deloitte Foundation are committed to supporting frontline workers, the most vulnerable, and underprivileged groups in society," adds Deloitte China Southern Region Managing Partner Edward Au. "We have been able to leverage our network of suppliers and regional procurement teams across China to do what we can to ensure Hong Kong has what it needs to fight back against the fifth wave." All of us at Deloitte China express our deep gratitude for the dedicated work of frontline workers at this challenging time. About the Deloitte FoundationThe Deloitte Foundation was established in Chongqing and Hong Kong in June 2015 to centralize the management of charitable donations and support Deloitte's corporate responsibility programs.About DeloitteDeloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more. Deloitte is a leading global provider of audit and assurance, consulting, financial advisory, risk advisory, tax and related services. Our global network of member firms and related entities in more than 150 countries and territories (collectively, the "Deloitte organization") serves four out of five Fortune Global 500 companies. Learn how Deloitte's approximately 345,000 people make an impact that matters at www.deloitte.com. Deloitte Asia Pacific Limited is a company limited by guarantee and a member firm of DTTL. Members of Deloitte Asia Pacific Limited and their related entities, each of which are separate and independent legal entities, provide services from more than 100 cities across the region, including Auckland, Bangkok, Beijing, Hanoi, Hong Kong, Jakarta, Kuala Lumpur, Manila, Melbourne, Osaka, Seoul, Shanghai, Singapore, Sydney, Taipei and Tokyo.The Deloitte brand entered the China market in 1917 with the opening of an office in Shanghai. Today, Deloitte China delivers a comprehensive range of audit & assurance, consulting, financial advisory, risk advisory and tax services to local, multinational and growth enterprise clients in China. Deloitte China has also made - and continues to make - substantial contributions to the development of China's accounting standards, taxation system and professional expertise. Deloitte China is a locally incorporated professional services organization, owned by its partners in China. To learn more about how Deloitte makes an Impact that Matters in China, please connect with our social media platforms at www2.deloitte.com/cn/en/social-media.This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms or their related entities (collectively, the "Deloitte organization") is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.2022. For information, contact Deloitte China.Contact: Ashley LeungTel: +852 2109 5261Email: asleung@deloitte.com.hkContact: Lyanna ChanTel: +852 2238 7111Email: lyachan@deloitte.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

12 1 月, 2022

冠科美博 (Apollomics Inc.) 将于 2022 年 1 月 26-27 日（周三、周四）举办线上投资者活动

Foster City, CA, Shanghai and Hangzhou, China, Jan 12, 2022 - (亚太商讯 via SEAPRWire.com) - 冠科美博（Apollomics Inc.），一家致力于发现和开发单药及组合肿瘤疗法的创新生物制药公司，今日宣布，管理团队将为来自美国和中国的参会者举办两场网络直播，冠科美博联合创始人、董事长兼首席执行官余国良博士将和联合创始人兼总裁 Sanjeev Redkar 博士、首席医学官余健鸿K. Peony Yu医学博士、首席财务官注册会计师 Wilson W. Cheung先生一起介绍公司的战略概要和公司产品管线的更新。会议日期/时间：1、英语场：1月26日上午11:00（美国太平洋时间）（美东1月26日下午2:00/中国1月27日凌晨3:00/欧洲1月26日晚上8:00）2、中文场：1月27日上午11:00（中国北京时间）（美国太平洋1月26日晚上7:00/美东1月26日晚上10:00/欧洲1月27日凌晨4:00）竭诚邀请所有相关人员通过冠科美博网站观看网络直播，页面链接地址：https://www.apollomicsinc.com/press-releases/events-presentations/https://www.apollomicsinc.com/zh-hans/新闻稿/活动和演示/网络直播的资料保留三个月。关于冠科美博（Apollomics Inc.）冠科美博（Apollomics Inc.）是一家创新型生物制药公司，致力于研发肿瘤靶向和免疫单药及其组合疗法。公司产品管线有多个处于不同开发阶段的项目，包括为恢复机体免疫系统识别能力和杀死癌细胞的新型人源化单克隆抗体和为针对失控的生长信号通路的靶向疗法。公司在中国杭州市、上海市和美国加州福斯特市均有运营实体。欲了解更多信息，请访问 www.apollomicsinc.com。联系方式：投资人联系人：Wilson W. Cheung首席财务官(650) 209-4436wcheung@apollomicsinc.com 公司联系人：张立平高级市场总监(86) 0571-83521933liping.zhang@apollomicsinc.com 中国媒体联系人：博达浩华国际财经传讯集团冯嘉莉 (Kelly Fung)总经理(852) 3150 6763kelly.fung@pordahavas.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

10 1 月, 2022

15th Asian Financial Forum opens

HONG KONG, Jan 10, 2022 - (ACN Newswire via SEAPRWire.com) - Organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the 15th Asian Financial Forum (AFF) opened today as an online-only event. AFF 2022 is a highlight event celebrating the 25th anniversary of the HKSAR. The two-day forum features 60 sessions including keynote speeches and in-depth discussions along with an array of activities such as exhibitions and the AFF Deal Flow Matchmaking Session. All activities at AFF 2022 will be streamed live on the event's virtual platform.Carrie Lam, Chief Executive of the HKSAR, delivered remarks at the opening ceremony of the 15th Asian Financial ForumMark Carney (R), United Nations Special Envoy on Climate Action and Finance, shared his insights on how to build a sustainable financial system. Mr Carney was introduced by Ronnie Chan, Chair, Hang Lung Properties Limited (L)Jean-Claude Trichet, Former President of the European Central BankUnder the theme "Navigating the Next Normal towards a Sustainable Future", more than 170 global business leaders, policymakers, financial and wealth management experts, entrepreneurs, tech giants and economists from 16 countries and regions speak at the AFF, and examine the key issues reshaping the economic landscape, including how industries can realise sustainable and inclusive development through impactful venture capital and business strategies.Carrie Lam, Chief Executive of the HKSAR, officiated at the forum's opening ceremony. In her opening remarks she noted that: "With 'One Country, Two Systems' back on the right track, international investors and observers have shown confidence in Hong Kong. The latest Global Financial Centres Index, in September last year, ranked Hong Kong third globally among the more than 100 financial centres assessed, behind only New York and London. Looking ahead, beyond the pandemic and the continuing cloud it raises over global economic growth, particularly associated with the Omicron variant, we see boundless possibilities."In his welcome remarks, Dr Peter K N Lam, Chairman of the HKTDC, said: "This year is especially meaningful because the AFF is also the first of many events to celebrate the 25th anniversary of the Hong Kong Special Administrative Region. While we are still tackling the pandemic, we are also looking beyond the pandemic to recovery, which is the main direction of the AFF theme this year. We have brought together policymakers and business leaders from around the world to discuss important global issues from an Asian perspective. This year, our event will again be held virtually, and I hope we can reach more people from around the world to share ideas and inspire each other."Three heavyweight financial ministers from Mainland China delivered special remarks during the opening session. They included Dr Shang Fulin, Director of the CPPCC Economic Affairs Committee, Former Chairman of the China Banking and Insurance Regulatory Commission, and Former Chairman of the China Securities Regulatory Commission; Dr Fang Xinghai, Vice Chairman, China Securities Regulatory Commission; and Xiao Yuanqi, Vice Chairman, China Banking and Insurance Regulatory Commission.Dr Shang noted: "Global openness requires cooperation, and a rules-based multilateral trading system is the cornerstone of economic globalisation and free trade. The international community must double-down on consensus-building and actions. We must also stand firm on maintaining openness, inclusiveness, dialogue and collaboration to jointly address global issues and challenges. This will enable us to promote stronger and greener global development and champion a community with a shared future."Mark Carney and Jean-Claude Trichet deliver keynote speeches on first dayMark Carney, United Nations Special Envoy on Climate Action and Finance, delivered a keynote address on the first day of AFF 2022. He shared his insights on how to build a sustainable financial system as a way of mitigating the liability and transitional threats posed by climate change. "From a general perspective, the risks of future pandemics have gone up because of climate change. And what is disappointing is that we have known of these risks of pandemics for a long period of time. The upfront investment against them in terms of healthcare capacity, testing, et cetera, is extremely modest relative to the cost, and we still haven't made those investments on the scale that we need. We have to take this seriously. It is compounded by climate change," Mr Carney said.Another distinguished speaker was Jean-Claude Trichet, Former President of the European Central Bank. He noted that the financial industry, regulators and policymakers should step up their concerted efforts in times of uncertainty.Global financial policymakers and experts discuss green finance and sustainable growthA plenary session chaired by Christopher Hui, Secretary for Financial Services and the Treasury of the HKSAR, was held following the opening session. Mr Hui joined together with an international panel of financial ministers, bank governors and policymakers to examine the characteristics of the post-COVID global economic new normal and discuss how the public and private sectors can collaborate to orient the global economy towards a green future with sustainable growth. The panellists included Vincent Van Peteghem, Deputy Prime Minister and Minister of Finance, Belgium; Mihaly Varga, Deputy Prime Minister and Minister of Finance, Hungary; Arkhom Termpittayapaisith, Minister of Finance, Thailand; Wimboh Santoso, Chairman of the Board of Commissioners, Financial Services Authority, Indonesia; Verena Ross, Chair, European Securities and Markets Authority; Jin Liqun, President and Chair, Asian Infrastructure Investment Bank; Muhammad Sulaiman Al Jasser, President, Islamic Development Bank; and Marcos Troyjo, President, New Development Bank.At a policy dialogue in the afternoon, Eddie Yue, Chief Executive, Hong Kong Monetary Authority, chaired a panel featuring Ashley Alder, Chief Executive Officer, Securities and Futures Commission; Benjamin E. Diokno, Central Bank Governor, Philippines; Klaas Knot, Chair, Financial Stability Board and President, De Nederlandsche Bank; Teresa Ko, Co-vice chair, IFRS Foundation; and Dr Ma Jun, Co-Chair of G20 Sustainable Finance Working Group, Co-Chair of IPSF Taxonomy Working Group; Chairman and President of Hong Kong Green Finance Association. The panel exchanged views on how the financial system can better support a sustainable global recovery while keeping climate-related financial risks at bay.Echoing the theme of AFF 2022, a panel discussion on "ESG & Sustainability" was also staged. Stewart James, Chief of Staff, Sustainability Policy & Regulation, HSBC, spoke with panellists including Andrew Erickson, Chief Productivity Officer, Head of International Business, State Street; Shinta Widjaja Kamdani, CEO, Sintesa Group; Amy Lo, Co-Head Wealth Management Asia Pacific, UBS Global Wealth Management; and Saker Nusseibeh, CEO, Federated Hermes International. The speakers shared their perspectives on how governments around the world, industry giants, financial institutions and philanthropists can work together towards the wider implementation of environmental, social and governance (ESG) to build a sustainable future.Financial and business leaders examine global economic outlookOther esteemed financial ministers and business leaders who spoke at AFF 2022 included Ju Weimin, Vice Chairman, President & CIO, China Investment Corporation, a sovereign wealth fund; Paul M Achleitner, Chairman of the Supervisory Board, Deutsche Bank AG; Tony O Elumelu, Group Chairman, United Bank for Africa (UBA) and Founder, Tony Elumelu Foundation; Bill Winters, Group Chief Executive, Standard Chartered plc; Tian Guoli, Chairman, Executive Director, China Construction Bank Corporation; Liu Jin, President, Bank of China Limited; Shriti Vadera, Group Chair, Prudential plc; and Douglas Flint, Chairman, abrdn plc.AFF Deal Flow Matchmaking Session and fintech exhibition held onlineFrom 10 to 12 January, the AFF Deal Flow Matchmaking Session is arranging a series of one -on-one matchmaking meetings on the virtual AFF platform to facilitate collaboration between project owners, potential business partners and investors. More than 600 investment projects, including over 200 ESG-related projects, are being showcased, covering sectors such as deep tech, digital technology and media, healthtech, education, infrastructure and real estate services.Online exhibitions are also being held during AFF 2022. At the Fintech Showcase, InnoVenture Salon, FintechHK Startup Salon and Global Investment Zone, more than 130 local and international financial institutions, tech companies, start-ups and investment agencies are showcasing an array of advanced technologies and unmissable investment opportunities in various countries and regions. Meanwhile, the HKTDC, Mizuho Bank and Eureka Nova, a start-up incubation and open innovation platform established by New World Development, come together for the first time for AFF Accelerate. It provides a platform for entrepreneurs and innovators to bring their next-generation technology solutions from concept to fruition and adoption in the business sector.Cryptonaire and eminent philanthropist speak on second dayTomorrow morning will see another keynote speaker Brett King, Founder and Executive Chairman of Moven, sharing perspectives on how the emergence of new fintech developments presents both opportunities and challenges for the banking and financial industries. Sam Bankman-Fried, Founder and CEO of cryptocurrency exchange FTX.com and the richest person in crypto, who is also a Forbes 30 Under 30 honouree, will talk about his entrepreneurial journey and the outlook for blockchain and cryptocurrency. In addition, philanthropist Michael Milken, widely known as one of the most influential thinkers in US finance, will share some of the positive changes that his philanthropic work has created for communities, while Miao Jianmin, Chairman, China Merchants Group, will share his views on Mainland China's carbon neutrality goals and green finance development.Other highlight sessions tomorrow include "Decentralised Future - Accelerating Blockchain Innovation for Digital Assets & Transaction" and "Innovation Investment in NFT - Trends and Opportunities", which will feature speakers such as Jason Bailey, Co-Founder & CEO, ClubNFT, and Francis Belin, President, Asia Pacific at Christie's.At the Family Office Symposium, co-organised by the HKTDC and the Private Wealth Management Association, Ronnie Chan, Chair, Hang Lung Properties; Adrian Cheng, Chief Executive Officer, New World Development; and Seri Cheah Cheng Hye, Co-Chairman and Co-Chief Investment Officer, Value Partners Group, will explore wealth management trends relating to family offices and discuss their development among Asian families.Furthermore, a series of thematic workshops, "Dialogues for Tomorrow" and fireside chats will examine the future of such sectors as energy, food and agriculture, digital wealth management, cloud computing, paytech and healthcare. The speakers will also explore opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area, venture capital trends and the net zero economy.Websites- Asian Financial Forum: https://www.asianfinancialforum.com/aff/en/- AFF programme: https://www.asianfinancialforum.com/aff/en/programme/programme- AFF speakers: https://www.asianfinancialforum.com/aff/en/speaker/main- Photo download: https://bit.ly/333AwMLMedia enquiriesPlease contact the HKTDC's Communications & Public Affairs Department:Janet Chan, Tel: +852 2584 4369, Email: janet.ch.chan@hktdc.orgClayton Lauw, Tel: +852 2584 4472, Email: clayton.y.lauw@hktdc.orgAgnes Wat, Tel: +852 2584 4554, Email: agnes.ky.wat@hktdc.orgAbout HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

5 1 月, 2022

Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)

LAUSANNE, Switzerland, Jan 5, 2022 - (ACN Newswire via SEAPRWire.com) - Oculis S.A. ("Oculis"), a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the appointment of Mr. Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022. Mr. Ding brings vast healthcare leadership experience, with a specific focus on China market.Mr. Ding will join the Oculis Executive Leadership Team, where his decades of experience in multinational pharmaceutical company operations will help drive the company forward as it continues to develop its product pipeline and scale globally. The appointment of Mr. Ding also further strengthens Oculis' development efforts in the Greater China region, following the establishment of a Hong Kong presence earlier in the year. Riad Sherif, M.D., CEO of Oculis, said: "We are delighted to have Webb join Oculis as our global Chief Operating Officer and General Manager, China. He brings decades of experience in healthcare across multiple segments, including unique experiences in successful brand launches and portfolio build up in the Greater China market. His in-depth knowledge of business development and licensing will be an invaluable asset to our global executive leadership team as we continue to develop a portfolio of transformative ophthalmology treatments to improve the sight and lives of patients."Webb Ding added: "I am excited to be joining Oculis, a company dedicated to transforming the lives of patients impacted by eye diseases. There are many patients around the world in need of effective, safe and easy-to-administer topical eye medicines such as those currently being developed by Oculis. I look forward to helping to bring these much-needed treatments to patients as soon as possible."Mr. Ding has more than 25 years of experience in general management, successful go-to-market strategies, business development and licensing, and operational excellence across multiple healthcare segments. He joins Oculis from Fresenius-Kabi, one of the top 10 multinational pharmaceutical companies in China, where he served as Country President for China, building market leadership and a strong competitive portfolio. Prior to Fresenius-Kabi, Mr. Ding spent more than 10 years with Novartis in China in leadership roles of increasing responsibility, culminating in his appointment as General Manager of Novartis Vaccines Greater China and Tianyuan Bio-Pharma. Mr. Ding was also a member of the Global Executive Committee of Novartis Vaccines.Prior to Novartis, Mr. Ding held various senior roles in sales, marketing and distribution at major pharmaceutical companies in China including Bristol Myers Squibb and Xi'an Janssen (a Johnson & Johnson company).Mr. Ding gained his Bachelor of Science in biochemistry from Wuhan University and completed an EMBA at the China Europe International Business School.About OculisHeadquartered in Lausanne, Switzerland with global operations in Europe, the U.S. and China, Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Oculis has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatments, which are non-invasive and represent an unprecedented technical advance for patients with retinal edema and front-of-the-eye diseases. In addition, Oculis' formulation discovery and innovation capabilities enable the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.To learn more, please visit www.oculis.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

4 1 月, 2022

冠科美博（Apollomics）首席执行官余国良博士当选为百华协会 (BayHelix Group) 董事会主席

Foster City, CA, Hangzhou and Shanghai, China, Jan 4, 2022 - (亚太商讯 via SEAPRWire.com) - 冠科美博（Apollomics Inc.）一家致力于发现和开发单药及组合肿瘤疗法的创新生物制药公司，今日宣布，冠科美博联合创始人、董事长兼首席执行官余国良博士最近被任命为百华协会董事会主席，此项任命自2022 年 1 月起生效。余博士表示：“成立20 年以来，百华协会一直是中国新兴企业与世界其他国家/地区联系的重要纽带之一，我很荣幸得到同行们的认可，让我有机会带领百华协会在全球生命科学生态圈内继续推动生物技术创新和拓展商业机会。冠科美博是一家专注于开发肿瘤创新疗法的生物技术公司，在中美两国均有运营实体，我们自成立以来一直与百华协会密切合作并共同成长。我期待通过我的专业知识和见解，与杰出的百华协会董事会成员及会员通力合作，进一步实现我们连接全球生物制药公司的目标。”关于百华协会百华协会是由全球生命科技和医药健康产业领域中的商业领袖组成的非营利性会员组织。我们的使命是促进生命科技和医药健康产业的发展。2001年，百华协会于旧金山湾区成立，现在我们在全球拥有800多位会员，主要集中在中美两地。百华协会致力于培育和创造商机，为社会提供和培养领导者，并在其成员之间建立沟通网络并分享信息和经验。多元化的会员基础涵盖了许多世界顶级制药和生物制药公司，顶尖的专业服务和投资机构，以及中美的新兴生物技术公司。百华会员是邀请制，超过三分之二的会员是“总裁级（ CEO, COO, CFO等）”的企业高层决策人物。他们中的大多数人都经过了科学和商业方面的交叉培训，精通中英文双语。百华已成为一个极具影响力的协会，作为桥梁将中国新兴的生物技术公司和制药企业与世界各地的同行联系起来。关于冠科美博（Apollomics Inc.）冠科美博（ Apollomics Inc.）是一家创新型生物制药公司，致力于研发肿瘤靶向和免疫单药及其组合疗法。公司产品管线有多个处于不同开发阶段的项目，包括为恢复机体免疫系统识别能力和杀死癌细胞的新型人源化单克隆抗体和为针对失控的生长信号通路的靶向疗法。公司在中国杭州市、上海市和美国加州福斯特市均有运营实体。欲了解更多信息，请访问 www.apollomicsinc.com。联系方式：投资人联系人：Wilson W. Cheung首席财务官电话：(650) 209-4436wcheung@apollomicsinc.com公司联系人：张立平高级市场总监电话：(86) 0571-83521933liping.zhang@apollomicsinc.com中国媒体联系人：博达浩华国际财经传讯集团冯嘉莉 (Kelly Fung) 总经理电话：(852) 3150 6763 kelly.fung@pordahavas.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)